000158752312/312025Q3falsehttp://fasb.org/us-gaap/2025#OtherAffiliatesMemberhttp://fasb.org/us-gaap/2025#OtherAffiliatesMemberhttp://fasb.org/us-gaap/2025#OtherAffiliatesMemberhttp://fasb.org/us-gaap/2025#OtherAffiliatesMemberhttp://www.knowles.com/20250930#OperatingExpensesRestructuringhttp://www.knowles.com/20250930#OperatingExpensesRestructuringhttp://www.knowles.com/20250930#OperatingExpensesRestructuringhttp://www.knowles.com/20250930#CostofGoodsSoldRestructuringChargeshttp://www.knowles.com/20250930#CostofGoodsSoldRestructuringChargeshttp://www.knowles.com/20250930#OperatingExpensesRestructuringhttp://www.knowles.com/20250930#OperatingExpensesRestructuringxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Ratekn:segments00015875232025-01-012025-09-3000015875232025-10-2400015875232025-07-012025-09-3000015875232024-07-012024-09-3000015875232024-01-012024-09-3000015875232025-09-3000015875232024-12-310001587523us-gaap:CommonStockMember2025-06-300001587523us-gaap:TreasuryStockCommonMember2025-06-300001587523us-gaap:AdditionalPaidInCapitalMember2025-06-300001587523us-gaap:RetainedEarningsMember2025-06-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-3000015875232025-06-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-300001587523us-gaap:TreasuryStockCommonMember2025-07-012025-09-300001587523us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-300001587523us-gaap:CommonStockMember2025-07-012025-09-300001587523us-gaap:CommonStockMember2025-09-300001587523us-gaap:TreasuryStockCommonMember2025-09-300001587523us-gaap:AdditionalPaidInCapitalMember2025-09-300001587523us-gaap:RetainedEarningsMember2025-09-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-300001587523us-gaap:CommonStockMember2024-06-300001587523us-gaap:TreasuryStockCommonMember2024-06-300001587523us-gaap:AdditionalPaidInCapitalMember2024-06-300001587523us-gaap:RetainedEarningsMember2024-06-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000015875232024-06-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001587523us-gaap:TreasuryStockCommonMember2024-07-012024-09-300001587523us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001587523us-gaap:CommonStockMember2024-07-012024-09-300001587523us-gaap:CommonStockMember2024-09-300001587523us-gaap:TreasuryStockCommonMember2024-09-300001587523us-gaap:AdditionalPaidInCapitalMember2024-09-300001587523us-gaap:RetainedEarningsMember2024-09-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-3000015875232024-09-300001587523us-gaap:CommonStockMember2024-12-310001587523us-gaap:TreasuryStockCommonMember2024-12-310001587523us-gaap:AdditionalPaidInCapitalMember2024-12-310001587523us-gaap:RetainedEarningsMember2024-12-310001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-09-300001587523us-gaap:TreasuryStockCommonMember2025-01-012025-09-300001587523us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-300001587523us-gaap:CommonStockMember2025-01-012025-09-300001587523us-gaap:CommonStockMember2023-12-310001587523us-gaap:TreasuryStockCommonMember2023-12-310001587523us-gaap:AdditionalPaidInCapitalMember2023-12-310001587523us-gaap:RetainedEarningsMember2023-12-310001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100015875232023-06-300001587523us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001587523us-gaap:TreasuryStockCommonMember2024-01-012024-09-300001587523us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001587523us-gaap:CommonStockMember2024-01-012024-09-3000015875232023-12-310001587523us-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:RestatementAdjustmentMember2025-04-012025-06-300001587523us-gaap:ResearchAndDevelopmentExpenseMembersrt:RestatementAdjustmentMember2025-04-012025-06-300001587523us-gaap:CostOfSalesMembersrt:RestatementAdjustmentMember2025-04-012025-06-300001587523srt:RestatementAdjustmentMember2025-01-012025-09-3000015875232025-01-012025-06-3000015875232025-06-270001587523us-gaap:RelatedPartyMember2025-07-012025-09-300001587523us-gaap:RelatedPartyMember2025-01-012025-09-300001587523us-gaap:RelatedPartyMember2025-09-300001587523us-gaap:RelatedPartyMember2024-12-3100015875232020-02-2400015875232022-04-2800015875232025-02-130001587523kn:ConsumerMEMSMicrophonesMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-12-270001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2025-01-012025-06-300001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2024-12-310001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2024-12-272025-03-310001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2025-01-012025-09-300001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2025-09-300001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2025-07-012025-09-300001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2024-07-012024-09-300001587523us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember2024-01-012024-09-3000015875232023-10-012023-12-310001587523us-gaap:LandMember2025-09-300001587523us-gaap:LandMember2024-12-310001587523us-gaap:BuildingAndBuildingImprovementsMember2025-09-300001587523us-gaap:BuildingAndBuildingImprovementsMember2024-12-310001587523us-gaap:EquipmentMember2025-09-300001587523us-gaap:EquipmentMember2024-12-310001587523kn:PrecisionDevicesMember2024-12-310001587523kn:MedTechSpecialtyAudioMember2024-12-310001587523kn:PrecisionDevicesMember2025-01-012025-09-300001587523kn:MedTechSpecialtyAudioMember2025-01-012025-09-300001587523kn:PrecisionDevicesMember2025-09-300001587523kn:MedTechSpecialtyAudioMember2025-09-300001587523us-gaap:TrademarksMember2025-09-300001587523us-gaap:TrademarksMember2024-12-310001587523us-gaap:CustomerRelationshipsMember2025-09-300001587523us-gaap:CustomerRelationshipsMember2024-12-310001587523us-gaap:UnpatentedTechnologyMember2025-09-300001587523us-gaap:UnpatentedTechnologyMember2024-12-310001587523us-gaap:OtherIntangibleAssetsMember2025-09-300001587523us-gaap:OtherIntangibleAssetsMember2024-12-310001587523us-gaap:TrademarksMember2025-09-300001587523us-gaap:TrademarksMember2024-12-310001587523us-gaap:EmployeeSeveranceMemberkn:PrecisionDevicesMember2025-07-012025-09-300001587523us-gaap:EmployeeSeveranceMemberkn:PrecisionDevicesMember2025-01-012025-09-300001587523kn:CostOfGoodsSoldRestructuringChargesMember2025-07-012025-09-300001587523us-gaap:EmployeeSeveranceMember2025-07-012025-09-300001587523kn:CostOfGoodsSoldRestructuringChargesMember2025-01-012025-09-300001587523us-gaap:EmployeeSeveranceMember2025-01-012025-09-300001587523us-gaap:RestructuringChargesMember2025-07-012025-09-300001587523kn:EmployeeSeveranceandFacilityClosingMember2025-07-012025-09-300001587523us-gaap:RestructuringChargesMember2025-01-012025-09-300001587523kn:EmployeeSeveranceandFacilityClosingMember2025-01-012025-09-300001587523kn:EmployeeSeveranceandFacilityClosingMember2024-07-012024-09-300001587523us-gaap:EmployeeSeveranceMemberkn:PrecisionDevicesMember2024-01-012024-09-300001587523us-gaap:OtherRestructuringMemberus-gaap:CorporateMember2024-07-012024-09-300001587523us-gaap:OtherRestructuringMemberus-gaap:CorporateMember2024-01-012024-09-300001587523us-gaap:EmployeeSeveranceMember2024-07-012024-09-300001587523us-gaap:EmployeeSeveranceMember2024-01-012024-09-300001587523kn:EmployeeSeveranceandFacilityClosingMember2024-01-012024-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2025-07-012025-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2024-07-012024-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2025-01-012025-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2024-01-012024-09-300001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2025-07-012025-09-300001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2024-07-012024-09-300001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2025-01-012025-09-300001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2024-01-012024-09-300001587523us-gaap:CorporateNonSegmentMember2025-07-012025-09-300001587523us-gaap:CorporateNonSegmentMember2024-07-012024-09-300001587523us-gaap:CorporateNonSegmentMember2025-01-012025-09-300001587523us-gaap:CorporateNonSegmentMember2024-01-012024-09-300001587523us-gaap:EmployeeSeveranceMember2024-12-310001587523us-gaap:FacilityClosingMember2024-12-310001587523us-gaap:FacilityClosingMember2025-01-012025-09-300001587523us-gaap:EmployeeSeveranceMember2025-09-300001587523us-gaap:FacilityClosingMember2025-09-300001587523us-gaap:FacilityClosingMemberus-gaap:AccruedLiabilitiesMember2025-09-300001587523us-gaap:FacilityClosingMemberus-gaap:AccruedLiabilitiesMember2024-12-310001587523kn:OtherAccruedExpensesMember2025-09-300001587523kn:OtherAccruedExpensesMember2024-12-310001587523us-gaap:OtherLiabilitiesMember2025-09-300001587523us-gaap:OtherLiabilitiesMember2024-12-310001587523kn:CreditFacilityDueJanuary22024Memberus-gaap:LineOfCreditMember2025-09-300001587523kn:CreditFacilityDueJanuary22024Memberus-gaap:LineOfCreditMember2024-12-310001587523kn:SellerNoteMember2025-09-300001587523kn:SellerNoteMember2024-12-310001587523kn:CreditFacilityDueFebruary82028Member2025-09-300001587523kn:September252023CreditFacilityAmendmentMember2023-09-250001587523kn:September252023CreditFacilityAmendmentMember2025-09-300001587523kn:CreditFacilityDueFebruary82028Membercurrency:EUR2025-09-300001587523kn:CreditFacilityDueFebruary82028Memberus-gaap:LetterOfCreditMember2025-09-300001587523kn:CreditFacilityDueFebruary82028Membersrt:MinimumMember2025-01-012025-09-300001587523kn:CreditFacilityDueFebruary82028Membersrt:MaximumMember2025-01-012025-09-300001587523kn:ApplicableMarginAlternateBaseRateMemberkn:CreditFacilityDueFebruary82028Membersrt:MinimumMember2025-01-012025-09-300001587523kn:ApplicableMarginAlternateBaseRateMemberkn:CreditFacilityDueFebruary82028Membersrt:MaximumMember2025-01-012025-09-300001587523kn:CreditFacilityDueJanuary22024Memberkn:LondonInterbankOfferedRateLIBORPriorTo2023Member2024-09-300001587523srt:WeightedAverageMemberus-gaap:LineOfCreditMember2025-01-012025-09-300001587523srt:WeightedAverageMemberus-gaap:LineOfCreditMember2024-01-012024-09-300001587523kn:CornellDubilierMemberkn:SellerNoteMemberkn:PrecisionDevicesMember2023-11-012023-12-310001587523kn:CornellDubilierMemberkn:PrecisionDevicesMember2023-11-012023-11-010001587523kn:SellerNoteMemberkn:CornellDubilierMemberkn:PrecisionDevicesMember2023-11-012023-12-310001587523kn:CornellDubilierMemberkn:SellerNoteMemberkn:PrecisionDevicesMember2025-03-310001587523kn:SellerNoteMemberkn:CornellDubilierMemberkn:PrecisionDevicesMember2023-11-012023-11-010001587523kn:CornellDubilierMemberkn:PrecisionDevicesMember2025-07-012025-09-300001587523kn:CornellDubilierMemberkn:PrecisionDevicesMember2024-07-012024-09-300001587523kn:CornellDubilierMemberkn:PrecisionDevicesMember2025-01-012025-09-300001587523kn:CornellDubilierMemberkn:PrecisionDevicesMember2024-01-012024-09-300001587523us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-09-300001587523us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-09-300001587523us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-09-300001587523us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-09-300001587523us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-09-300001587523us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300001587523us-gaap:EmployeeStockOptionMember2024-12-310001587523us-gaap:EmployeeStockOptionMember2025-01-012025-09-300001587523us-gaap:EmployeeStockOptionMember2025-09-300001587523us-gaap:RestrictedStockUnitsRSUMember2024-12-310001587523us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-300001587523us-gaap:RestrictedStockUnitsRSUMember2025-09-300001587523srt:MinimumMemberus-gaap:PerformanceSharesMember2025-01-012025-09-300001587523srt:MaximumMemberus-gaap:PerformanceSharesMember2025-01-012025-09-300001587523us-gaap:PerformanceSharesMember2025-02-182025-02-180001587523us-gaap:PerformanceSharesMember2025-02-180001587523srt:MinimumMemberus-gaap:PerformanceSharesMember2025-02-182025-02-180001587523srt:MaximumMemberus-gaap:PerformanceSharesMember2025-02-182025-02-180001587523us-gaap:PerformanceSharesMember2024-12-310001587523us-gaap:PerformanceSharesMember2025-01-012025-09-300001587523us-gaap:PerformanceSharesMember2025-09-300001587523us-gaap:RetainedEarningsMember2025-07-012025-09-300001587523us-gaap:RetainedEarningsMember2024-07-012024-09-300001587523us-gaap:RetainedEarningsMember2025-01-012025-09-300001587523us-gaap:RetainedEarningsMember2024-01-012024-09-300001587523us-gaap:StockCompensationPlanMember2025-01-012025-09-300001587523us-gaap:StockCompensationPlanMember2025-07-012025-09-300001587523us-gaap:StockCompensationPlanMember2024-07-012024-09-300001587523us-gaap:StockCompensationPlanMember2024-01-012024-09-300001587523us-gaap:OperatingSegmentsMember2025-07-012025-09-300001587523us-gaap:OperatingSegmentsMember2024-07-012024-09-300001587523us-gaap:OperatingSegmentsMember2025-01-012025-09-300001587523us-gaap:OperatingSegmentsMember2024-01-012024-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2025-09-300001587523us-gaap:OperatingSegmentsMemberkn:PrecisionDevicesMember2024-12-310001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2025-09-300001587523us-gaap:OperatingSegmentsMemberkn:MedTechSpecialtyAudioMember2024-12-310001587523us-gaap:CorporateNonSegmentMember2025-09-300001587523us-gaap:CorporateNonSegmentMember2024-12-310001587523country:US2025-07-012025-09-300001587523country:US2024-07-012024-09-300001587523country:US2025-01-012025-09-300001587523country:US2024-01-012024-09-300001587523srt:AsiaMember2025-07-012025-09-300001587523srt:AsiaMember2024-07-012024-09-300001587523srt:AsiaMember2025-01-012025-09-300001587523srt:AsiaMember2024-01-012024-09-300001587523srt:EuropeMember2025-07-012025-09-300001587523srt:EuropeMember2024-07-012024-09-300001587523srt:EuropeMember2025-01-012025-09-300001587523srt:EuropeMember2024-01-012024-09-300001587523kn:OtherAmericasMember2025-07-012025-09-300001587523kn:OtherAmericasMember2024-07-012024-09-300001587523kn:OtherAmericasMember2025-01-012025-09-300001587523kn:OtherAmericasMember2024-01-012024-09-300001587523kn:OtherGeographicalLocationsMember2025-07-012025-09-300001587523kn:OtherGeographicalLocationsMember2024-07-012024-09-300001587523kn:OtherGeographicalLocationsMember2025-01-012025-09-300001587523kn:OtherGeographicalLocationsMember2024-01-012024-09-300001587523kn:JeffreyNiewMember2025-07-012025-09-300001587523kn:JeffreyNiewMember2025-08-132025-08-130001587523kn:JeffreyNiewMember2025-08-130001587523kn:JohnAndersonMember2025-07-012025-09-300001587523kn:JohnAndersonMember2025-08-222025-08-220001587523kn:JohnAndersonMember2025-08-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025.

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36102

Knowles Corporation

(Exact name of registrant as specified in its charter)


Delaware			90-1002689
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

1151 Maplewood Drive, Itasca, IL

(Address of Principal Executive Offices)

60143

(Zip Code)

(630) 250-5100

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common stock, $0.01 par value per share

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☑

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☑

The number of shares outstanding of the registrant’s common stock as of October 24, 2025 was 85,151,884.

Table of Contents

Knowles Corporation

Form 10-Q

Table of Contents


		Page
PART I — FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
	Consolidated Statements of Earnings (unaudited) for the three and nin e months ended September 30, 2025 and 2024	1
	Consolidated Statements of Comprehensive Earnings (unaudited) for the three and nine months ended September 30, 2025 and 2024	2
	Consolidated Balance Sheets (unaudited) at September 30, 2025 and December 31, 2024	3
	Consolidated Statements of Stockholders' Equity (unaudited) for the three and nine months ended September 30, 2025 and 2024	4
	Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and 2024	6
	Notes to Consolidated Financial Statements (unaudited)	7
Forward-Looking Statements		25
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	43
Item 4.	Controls and Procedures	43

PART II — OTHER INFORMATION		43
Item 1.	Legal Proceedings	43
Item 1A.	Risk Factors	43
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44


Item 5.	Other Information	44
Item 6.	Exhibits	45
SIGNATURES		46

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements

KNOWLES CORPORATION

CONSOLIDATED STATEMENTS OF EARNINGS

(in millions, except per share amounts)

(unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Revenues	$	152.9	$	142.5	$	431.0	$	411.0
Cost of goods sold	82.8		79.5		242.9		235.7
Impairment charges	—		—		3.6		—

Restructuring charges - cost of goods sold	0.2		0.1		0.7		1.4
Gross profit	69.9		62.9		183.8		173.9
Research and development expenses	10.0		10.2		29.7		29.2
Selling and administrative expenses	34.0		33.9		107.1		106.8

Restructuring charges	0.1		0.1		2.5		1.5
Operating expenses	44.1		44.2		139.3		137.5
Operating earnings	25.8		18.7		44.5		36.4
Interest expense, net	2.3		3.9		7.5		12.9
Other expense, net	1.2		2.6		2.6		2.5

Earnings before income taxes and discontinued operations	22.3		12.2		34.4		21.0
Provision for income taxes	4.3		3.0		9.0		8.0
Earnings from continuing operations	18.0		9.2		25.4		13.0
Loss from discontinued operations, net	(0.6)		(8.7)		(2.2)		(269.3)
Net earnings (loss)	$	17.4	$	0.5	$	23.2	$	(256.3)

Earnings per share from continuing operations:
Basic	$	0.21	$	0.10	$	0.29	$	0.15
Diluted	$	0.21	$	0.10	$	0.29	$	0.14

Loss per share from discontinued operations:
Basic	$	(0.01)	$	(0.09)	$	(0.02)	$	(3.02)
Diluted	$	(0.01)	$	(0.09)	$	(0.03)	$	(2.98)

Net earnings (loss) per share:
Basic	$	0.20	$	0.01	$	0.27	$	(2.87)
Diluted	$	0.20	$	0.01	$	0.26	$	(2.84)

Weighted-average common shares outstanding:
Basic	85.8		88.7		86.8		89.2
Diluted	87.3		89.7		88.1		90.2

See accompanying Notes to Consolidated Financial Statements

Table of Contents

KNOWLES CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE EARNINGS

(in millions)

(unaudited)


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Net earnings (loss)	$	17.4	$	0.5	$	23.2	$	(256.3)

Other comprehensive (loss) earnings, net of tax



Foreign currency translation	0.4		17.1		6.5		10.5

Employee benefit plans:


Amortization or settlement of actuarial losses and prior service costs	0.1		0.3		0.4		0.6
Net change in employee benefit plans	0.1		0.3		0.4		0.6

Changes in fair value of cash flow hedges:
Unrealized net (losses) gains arising during period	(0.6)		2.5		1.9		(0.1)
Net (gains) losses reclassified into earnings	(0.3)		(0.2)		0.1		1.1
Total cash flow hedges	(0.9)		2.3		2.0		1.0

Other comprehensive (loss) earnings, net of tax	(0.4)		19.7		8.9		12.1

Comprehensive earnings (loss)	$	17.0	$	20.2	$	32.1	$	(244.2)

See accompanying Notes to Consolidated Financial Statements

Table of Contents

KNOWLES CORPORATION

CONSOLIDATED BALANCE SHEETS

(in millions, except share and per share amounts)

(unaudited)


	September 30, 2025		December 31, 2024
Current assets:
Cash and cash equivalents	$	92.5	$	130.1

Receivables, net of allowances of $0.1	107.7		105.0
Inventories	123.9		118.0
Prepaid and other current assets	10.1		8.3


Total current assets	334.2		361.4
Property, plant, and equipment, net	130.9		130.1
Goodwill	270.2		269.8
Intangible assets, net	145.3		157.4
Operating lease right-of-use assets	19.7		8.6
Investment in affiliate	77.2		77.2
Other assets and deferred charges	110.7		113.7

Total assets	$	1,088.2	$	1,118.2

Current liabilities:
Current maturities of long-term debt	$	72.3	$	68.5
Accounts payable	41.2		58.5
Accrued compensation and employee benefits	26.3		29.4
Operating lease liabilities	3.8		3.9
Other accrued expenses	25.3		33.6
Federal and other taxes on income	7.1		3.7

Total current liabilities	176.0		197.6

Long-term debt	104.0		134.0
Deferred income taxes	1.1		1.1
Long-term operating lease liabilities	16.9		5.8
Other liabilities	38.4		23.7

Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred stock - $0.01 par value; 10,000,000 shares authorized; none issued	—		—
Common stock - $0.01 par value; 400,000,000 shares authorized; 99,464,987 and 85,151,884 shares issued and outstanding at September 30, 2025, respectively, and 98,551,188 and 87,358,659 shares issued and outstanding at December 31, 2024, respectively	1.0		1.0
Treasury stock - at cost; 14,313,103 and 11,192,529 shares at September 30, 2025 and December 31, 2024, respectively	(260.7)		(205.2)
Additional paid-in capital	1,731.1		1,711.9
Accumulated deficit	(590.4)		(613.6)
Accumulated other comprehensive loss	(129.2)		(138.1)

Total stockholders' equity	751.8		756.0

Total liabilities and stockholders' equity	$	1,088.2	$	1,118.2

See accompanying Notes to Consolidated Financial Statements

Table of Contents

KNOWLES CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in millions, except share amounts)

(unaudited)


	Common Stock			Treasury Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
	Shares Issued	Amount		Shares	Amount
Balance at June 30, 2025	99,262,597	$	1.0	(13,374,991)	$	(240.4)	$	1,722.1	$	(607.8)	$	(128.8)	$	746.1
Net earnings	—	—		—	—		—		17.4		—		17.4
Other comprehensive loss, net of tax	—	—		—	—		—		—		(0.4)		(0.4)
Repurchase of common stock	—	—		(938,112)	(20.0)		—		—		—		(20.0)
Excise tax on repurchase of common stock	—	—		—	(0.3)		—		—		—		(0.3)
Stock-based compensation expense	—	—		—	—		5.9		—		—		5.9
Exercise of stock options	197,758	—		—	—		3.3		—		—		3.3



Restricted stock unit settlement, net of tax	4,632	—		—	—		(0.2)		—		—		(0.2)
Balance at September 30, 2025	99,464,987	$	1.0	(14,313,103)	$	(260.7)	$	1,731.1	$	(590.4)	$	(129.2)	$	751.8

	Common Stock			Treasury Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
	Shares Issued	Amount		Shares	Amount
Balance at June 30, 2024	98,031,163	$	1.0	(9,637,821)	$	(176.3)	$	1,698.3	$	(632.6)	$	(137.4)	$	753.0
Net earnings	—	—		—	—		—		0.5		—		0.5
Other comprehensive earnings, net of tax	—	—		—	—		—		—		19.7		19.7
Repurchase of common stock	—	—		(253,264)	(4.5)		—		—		—		(4.5)

Stock-based compensation expense	—	—		—	—		7.3		—		—		7.3
Exercise of stock options	136,588	—		—	—		1.9		—		—		1.9



Restricted stock unit settlement, net of tax	103,836	—		—	—		(0.5)		—		—		(0.5)
Balance at September 30, 2024	98,271,587	$	1.0	(9,891,085)	$	(180.8)	$	1,707.0	$	(632.1)	$	(117.7)	$	777.4

See accompanying Notes to Consolidated Financial Statements

Table of Contents

KNOWLES CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in millions, except share amounts)

(unaudited)
































	Common Stock			Treasury Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
	Shares Issued	Amount		Shares	Amount
Balance at December 31, 2024	98,551,188	$	1.0	(11,192,529)	$	(205.2)	$	1,711.9	$	(613.6)	$	(138.1)	$	756.0
Net earnings	—	—		—	—		—		23.2		—		23.2
Other comprehensive earnings, net of tax	—	—		—	—		—		—		8.9		8.9
Repurchase of common stock	—	—		(3,120,574)	(55.0)		—		—		—		(55.0)
Excise tax on repurchase of common stock	—	—		—	(0.5)		—		—		—		(0.5)
Stock-based compensation expense	—	—		—	—		22.4		—		—		22.4
Exercise of stock options	241,118	—		—	—		3.9		—		—		3.9



Restricted and performance stock unit settlement, net of tax	672,681	—		—	—		(7.1)		—		—		(7.1)
Balance at September 30, 2025	99,464,987	$	1.0	(14,313,103)	$	(260.7)	$	1,731.1	$	(590.4)	$	(129.2)	$	751.8

	Common Stock			Treasury Stock			Additional Paid-In Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Stockholders' Equity
	Shares Issued	Amount		Shares	Amount
Balance at December 31, 2023	97,297,703	$	1.0	(8,204,832)	$	(151.2)	$	1,689.9	$	(375.8)	$	(129.8)	$	1,034.1
Net loss	—	—		—	—		—		(256.3)		—		(256.3)
Other comprehensive earnings, net of tax	—	—		—	—		—		—		12.1		12.1
Repurchase of common stock	—	—		(1,686,253)	(29.5)		—		—		—		(29.5)
Excise tax on repurchase of common stock	—	—		—	(0.1)		—		—		—		(0.1)
Stock-based compensation expense	—	—		—	—		21.4		—		—		21.4
Exercise of stock options	146,913	—		—	—		2.1		—		—		2.1



Restricted and performance stock unit settlement, net of tax	826,971	—		—	—		(6.4)		—		—		(6.4)
Balance at September 30, 2024	98,271,587	$	1.0	(9,891,085)	$	(180.8)	$	1,707.0	$	(632.1)	$	(117.7)	777.4

See accompanying Notes to Consolidated Financial Statements

Table of Contents

KNOWLES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)


	Nine Months Ended September 30,
	2025		2024
Operating Activities
Net earnings (loss)	$	23.2	$	(256.3)
Adjustments to reconcile net earnings (loss) to cash from operating activities:
Goodwill impairment	—		262.5
Depreciation and amortization	27.1		40.7
Stock-based compensation	22.4		21.4
Deferred income taxes	4.3		0.7
Non-cash interest expense and amortization of debt issuance costs	4.2		6.4
Fixed asset impairment	3.6		—
Loss on sale of business	1.6		2.3
Non-cash restructuring charges	—		0.3


Loss (gain) on sale of fixed assets	0.1		(1.1)
Gain on sale of technology	—		(7.2)







Other, net	5.2		7.4
Changes in assets and liabilities (excluding effects of foreign exchange):
Receivables, net	(3.8)		(8.4)
Inventories	(4.8)		11.2
Prepaid and other current assets	(1.5)		(0.3)

Accounts payable	(20.8)		5.8
Accrued compensation and employee benefits	(3.4)		3.5
Other accrued expenses	(7.8)		(3.1)
Accrued taxes	3.2		15.3
Other non-current assets and non-current liabilities	14.0		(6.1)
Net cash provided by operating activities	66.8		95.0

Investing Activities

Proceeds from the sale of technology	—		7.2

Capital expenditures	(16.8)		(10.3)


Purchase of investments	(1.6)		(0.5)
Proceeds from the sale of investments	1.6		0.5
Proceeds from seller loan repayment	0.5		—



Net cash used in investing activities	(16.3)		(3.1)

Financing Activities
Repurchase of common stock	(55.0)		(29.5)
Payments under revolving credit facility	(30.0)		(130.0)
Borrowings under revolving credit facility	—		78.0




Tax on restricted and performance stock unit vesting and stock option exercises	(7.1)		(6.4)

Payments of finance lease obligations	(0.4)		(1.4)

Proceeds from exercise of stock options	3.9		2.1






Net cash used in financing activities	(88.6)		(87.2)

Effect of exchange rate changes on cash and cash equivalents	0.5		0.6

Net (decrease) increase in cash and cash equivalents	(37.6)		5.3
Cash and cash equivalents at beginning of period	130.1		87.3


Cash and cash equivalents at end of period	$	92.5	$	92.6

Supplemental information - cash paid for:
Income taxes	$	7.5	$	8.3
Interest	$	6.2	$	9.7

See accompanying Notes to Consolidated Financial Statements


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

1. Basis of Presentation

Background - Knowles Corporation (NYSE:KN) is a leading manufacturer of specialty electronic components. The Company designs parts that perform unique and critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, the Company enables businesses to succeed in the most demanding applications across medtech, defense, and industrial markets. Knowles high performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, balanced armature speakers, and miniaturization products enable and enhance the performance of customer products. The Company's focus on the customer, combined with unique technology, proprietary manufacturing techniques, and global operational expertise enable it to deliver innovative solutions across multiple applications. References to "Knowles," "the Company," "we," "our," and "us" refer to Knowles Corporation and its consolidated subsidiaries.

Financial Statement Presentation - The accompanying unaudited interim Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission ("SEC") for quarterly reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (“GAAP” or “U.S. GAAP”) for complete financial statements. These unaudited interim Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the year ended December 31, 2024 included in the Company’s Annual Report on Form 10-K.

The accompanying unaudited interim Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may differ from those estimates. Management uses historical experience and all available information to make these estimates. The unaudited interim Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair statement of results for these interim periods.

On December 27, 2024, the Company completed the sale of the Consumer MEMS Microphones ("CMM") segment to Syntiant Corp. ("Syntiant"). See Note 3. Discontinued Operations for additional information related to this transaction. The results of operations for CMM have been classified as discontinued operations for all periods presented.

Corrections of Errors - During the nine months ended September 30, 2025, the Company identified an error in its historical financial results related to stock-based compensation expense for those individuals that are nearing or have reached retirement eligibility as defined by the equity compensation plan. This error resulted in the understatement of stock-based compensation expense for the years ended December 31, 2024, 2023, and 2022. During the nine months ended September 30, 2025, the Company corrected its stock-based compensation expense, which resulted in increases to Selling and administrative expenses of $0.9 million, Research and development expenses of $0.1 million, and Cost of goods sold of $0.1 million. This correction decreased Earnings before income taxes and discontinued operations and Earnings from continuing operations by $1.1 million and $1.0 million, respectively, for the nine months ended September 30, 2025.

In addition, during the nine months ended September 30, 2025, the Company identified an error in its historical financial results related to working capital adjustments and costs associated with the disposal of CMM in the fourth quarter of 2024. This error resulted in the overstatement of the gain on disposal of business reflected in Loss from discontinued operations, net during the year ended December 31, 2024. During the nine months ended September 30, 2025, the Company corrected this error, resulting in an increase to Loss from discontinued operations, net of $1.3 million.

The Company evaluated the impact of these errors in accordance with Accounting Standards Codification ("ASC") 250, Accounting Changes and Error Corrections, and determined that they were not material to the consolidated financial statements for the current interim period or to any previously reported annual or interim periods.

Transactions with Syntiant - As partial consideration for the sale of CMM on December 27, 2024, the Company received Series D-2 preferred stock of Syntiant. See Note 3. Discontinued Operations for additional information related to this transaction. The Company accounts for this investment using the cost method, measured at its historical cost of $77.2 million, which was the fair value of the consideration received from Syntiant. This amount is reflected as “Investment in affiliate” on the Consolidated Balance Sheet.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

In connection with the sale of CMM, the Company provided financing of $6.4 million to Syntiant, which was utilized to fund Syntiant's requirement to have $40.0 million of cash on its balance sheet at closing. This note is junior to Syntiant's debt financing and matures on March 28, 2029 and bears interest at the prime rate until six months after the closing date of the sale, at which time the interest rate increased to 13.0%. The balance of this note was $5.9 million and $6.4 million as of September 30, 2025 and December 31, 2024, respectively, and is classified within "Other assets and deferred charges" on the Consolidated Balance Sheet.

The Company shares in certain separation costs with Syntiant related to the sale of CMM pursuant to a credit for up to $13.5 million, which it may apply to specified separation costs post-closing. The balance of the separation credit was $6.2 million and $13.5 million at September 30, 2025 and December 31, 2024, respectively and is classified within "Other accrued expenses" on the Consolidated Balance Sheet. As the balance of the separation credit is now below the $6.5 million contractual threshold, future costs will be shared equally by the Company and Syntiant.

The Company leases portions of its facilities to Syntiant, for which lease payments to date of $2.6 million have been applied to the separation credit. The Company also subleases portions of its manufacturing facilities to Syntiant at cost. The portion of operating lease right-of-use assets subleased by Syntiant totaled $5.2 million and $0.3 million at September 30, 2025 and December 31, 2024, respectively.

The Company recognized revenue totaling $4.4 million and $12.7 million during the three and nine months ended September 30, 2025, respectively, related to transactions with Syntiant. These revenues are reflected in the results of the MedTech & Specialty Audio segment. Receivables, net include $4.0 million and $1.8 million due from Syntiant at September 30, 2025 and December 31, 2024, respectively, related to these sales transactions and amounts related to the sale of CMM.

In 2025 the Company engaged with Syntiant to sell certain machinery and equipment associated with the MedTech & Specialty Audio segment for a nominal selling price. The Company recorded an impairment charge of $3.6 million for the nine months ended September 30, 2025 to write down the carrying value of these assets to fair value based on the selling price.

Share Repurchase Program - On February 24, 2020, the Company announced that its Board of Directors had authorized a share repurchase program of up to $100.0 million of the Company's common stock. On April 28, 2022, the Company announced that its Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value, for a total of $400.0 million of aggregate value. The timing and amount of any shares repurchased will be determined by the Company based on its evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. The Company is not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock.

During the nine months ended September 30, 2025 and 2024, the Company repurchased 3,120,574 and 1,686,253 shares of common stock for a total of $55.0 million and $29.5 million, respectively. At September 30, 2025, the Company had $139.0 million remaining that may yet be repurchased under the share repurchase program.

Non-cash Operating Activities - Operating lease liabilities arising from obtaining right-of-use assets for the nine months ended September 30, 2025 and 2024 were $15.6 million and $0.6 million, respectively. The 2024 amount reflects both continuing and discontinued operations.

Non-cash Investing Activities - Purchases of property, plant, and equipment included in accounts payable at September 30, 2025 and 2024 were $3.4 million and $1.0 million, respectively. The 2024 amount reflects both continuing and discontinued operations. These non-cash amounts are not reflected as "Capital expenditures" within Investing Activities on the Consolidated Statements of Cash Flows for the respective periods.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

2. Recent Accounting Standards

In November 2023, the Financial Accounting Standards Board ("FAB") issued Accounting Standards Update ("ASU") 2023-07 to expand reportable segment disclosure requirements. This guidance requires that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss. Additionally, this standard requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. The Company retroactively adopted this standard beginning with its annual reporting for the year ended December 31, 2024 and its interim reporting for the three months ended March 31, 2025. See Note 15. Segment Information.

In December 2023, the FASB issued ASU 2023-09 to enhance the transparency of income tax disclosures. This guidance requires that public business entities disclose, on an annual basis, specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes and the judgment used in categorizing the reconciling items. This guidance also requires that all entities disclose, on an annual basis, the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and the amount of income taxes paid (net of refunds received) disaggregated by those individual jurisdictions equal to or greater than 5 percent of the total. This standard is effective for the Company for its annual reporting for the year ended December 31, 2025. Early adoption is permitted. The standard requires adoption on a prospective basis, although retrospective adoption is permitted. The Company does not expect the adoption of this standard to have a significant impact upon the financial statements.

In November 2024, the FASB issued ASU 2024-03 to provide additional information about specific expense categories in the notes to the financial statements at interim and annual reporting periods. This guidance requires that a public business entity disclose amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption presented on the face of the income statement and a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. This standard also requires an entity disclose the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. This standard is effective for the Company for its annual reporting for the year ended December 31, 2027 and for interim reporting for the three months ended March 31, 2028. Early adoption is permitted. This standard may be applied either prospectively to the financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the impact of this ASU on its financial statements.

3. Discontinued Operations

On December 27, 2024, the Company completed the sale of the CMM segment to Syntiant. The total consideration for this transaction was approximately $141.9 million, consisting of $63.6 million in cash ($58.0 million net of cash sold), Syntiant Series D-2 preferred stock with a fair value of $77.2 million, and $1.1 million for estimated purchase price adjustments. The purchase price adjustment is still being finalized and is subject to change. The Company shares in certain separation costs pursuant to a credit for up to $13.5 million, which the buyer may apply to specified separation costs post-closing. The Company incurred costs to sell related to this transaction of $5.8 million.

As part of its post-transaction review, the Company recorded net adjustments of $1.6 million to the loss on disposal of CMM during the nine months ended September 30, 2025. This amount includes losses of $1.8 million ($1.3 million, net of tax) related to working capital adjustments and costs associated with the transaction that occurred in the fourth quarter of 2024, but were not recorded at that time. See also Note 1. Basis of Presentation.

The disposition of CMM meets the criteria described in ASC 205-20, Presentation of Financial Statements – Discontinued Operations. In accordance with this guidance, the Company has reclassified the results of operations of CMM to discontinued operations for all periods presented as this disposal represents a strategic shift that has a major effect on the Company’s results of operations.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

Results of the Company’s discontinued operations were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
Revenues	$	—	$	72.8	$	—	$	208.9
Cost of goods sold	—		53.4		—		154.1
Gain on sale of fixed assets	—		—		—		(1.1)

Gross profit	—		19.4		—		55.9
Research and development expenses	—		10.1		0.4		32.6
Selling and administrative expenses	—		7.0		0.4		20.6
Goodwill impairment	—		13.1		—		262.5

Operating expenses	—		30.2		0.8		315.7
Operating loss	—		(10.8)		(0.8)		(259.8)


Loss on disposal of business	—		2.3		1.6		2.3
Gain on sale of technology, net	—		—		—		(5.4)
Loss from discontinued operations before taxes	—		(13.1)		(2.4)		(256.7)
Provision for (benefit from) income taxes	0.6		(4.4)		(0.2)		12.6
Loss from discontinued operations, net	$	(0.6)	$	(8.7)	$	(2.2)	$	(269.3)

During the three and nine months ended September 30, 2024, the Company recorded goodwill impairment charges of $13.1 million and $262.5 million, respectively, to write down the carrying value of CMM to its fair value. In addition, the Company recorded an impairment charge of $2.3 million during the three and nine months ended September 30, 2024 to write down the carrying value of CMM to its fair value less costs to sell. This impairment is reflected as "Loss on disposal of business" in the results of discontinued operations above.

During the nine months ended September 30, 2024, the Company sold certain technology related to CMM to a third party for total proceeds of $7.2 million. After transaction costs of $1.8 million, the Company recognized a net gain on the sale of this asset of $5.4 million during the nine months ended September 30, 2024. This gain is reflected as “Gain on sale of technology, net” in the results of discontinued operations above.

In 2023, the Company entered into an agreement to sell certain of its machinery and equipment related to CMM to a third party for total proceeds of $11.4 million, which were received in their entirety in 2023. During the nine months ended September 30, 2024, the Company recorded an additional gain on sale of these assets of approximately $1.1 million as a result of changing its estimate on the amount owed to the third party. This gain is reflected as "Gain on sale of fixed assets" in the results of discontinued operations above.

As the Consolidated Statement of Cash Flows includes the results of CMM in its net cash provided by (used in) operating, investing, and financing activities, the Company has provided the following information related to CMM in accordance with ASC 205-20:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
Depreciation	$	—	$	2.6	$	—	$	8.1
Amortization of intangible assets	—		1.5		—		4.5
Capital expenditures	—		0.2		—		0.9


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

4. Inventories

The following table details the major components of inventories:


(in millions)	September 30, 2025		December 31, 2024
Raw materials	$	97.9	$	94.2
Work in progress	28.8		26.1
Finished goods	43.5		35.5
Subtotal	170.2		155.8
Less reserves	(46.3)		(37.8)
Total	$	123.9	$	118.0

5. Property, Plant, and Equipment, net

The following table details the major components of property, plant, and equipment, net:


(in millions)	September 30, 2025		December 31, 2024
Land	$	14.1	$	14.1
Buildings and improvements	98.7		117.2
Machinery, equipment, and other	281.3		276.7
Subtotal	394.1		408.0
Less accumulated depreciation	(263.2)		(277.9)
Total	$	130.9	$	130.1

Depreciation expense totaled $5.0 million for both the three months ended September 30, 2025 and 2024. For the nine months ended September 30, 2025 and 2024 depreciation expense totaled $15.0 million and $15.3 million, respectively.

During the nine months ended September 30, 2025, the Company recorded an impairment charge of $3.6 million to write down the carrying value of certain machinery and equipment to its selling price. See also "Transactions with Syntiant" in Note 1. Basis of Presentation.

6. Goodwill and Other Intangible Assets

The changes in the carrying value of goodwill by reportable segment for the nine months ended September 30, 2025 are as follows:


(in millions)	Precision Devices		MedTech & Specialty Audio		Total


Balance at December 31, 2024	$	132.1	$	137.7	$	269.8


Foreign currency translation	0.4		—		0.4
Balance at September 30, 2025	$	132.5	$	137.7	$	270.2


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

Other Intangible Assets

The gross carrying value and accumulated amortization for each major class of intangible assets are as follows:


	September 30, 2025				December 31, 2024
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Amortized intangible assets:
Trademarks	$	15.2	$	2.5	$	15.2	$	1.7

Customer relationships	118.5		36.5		118.5		27.3
Developed technology	26.3		8.1		26.3		6.0
Other	0.8		0.4		0.8		0.4
Total	160.8		47.5		160.8		35.4
Unamortized intangible assets:
Trademarks	32.0				32.0


Total intangible assets, net	$	145.3			$	157.4

Amortization expense totaled $4.0 million and $4.2 million for the three months ended September 30, 2025 and 2024, respectively. For the nine months ended September 30, 2025 and 2024 amortization expense totaled $12.1 million and $12.8 million, respectively. Amortization expense for the next five years, based on current definite-lived intangible balances, is estimated to be as follows:


(in millions)
Q4 2025	$	4.1
2026	16.0
2027	16.0
2028	15.2
2029	12.8
2030 and thereafter	49.2
Total	$	113.3

7. Other liabilities

The following table details the major components of other liabilities:


(in millions)	September 30, 2025		December 31, 2024
Deferred revenue	$	19.8	$	—
Deferred compensation	15.3		14.7
Unrecognized tax benefits	2.6		2.5
Long-term finance lease liabilities	0.4		0.4
Restructuring and exit costs	—		4.8
Long-term hedging liability	—		1.0
Other	0.3		0.3
Total	$	38.4	$	23.7


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

8. Restructuring and Related Activities

Restructuring and related activities are designed to better align the Company's operations with current market conditions through targeted facility consolidations, headcount reductions, and other measures to further optimize operations.

The Company recorded restructuring charges of $0.3 million and $3.2 million during the three and nine months ended September 30, 2025, respectively, related to headcount reductions across the Company primarily to rightsize operating expenses subsequent to the sale of CMM. The Company recorded charges of $0.2 million and $0.7 million within Gross profit for the three and nine months ended September 30, 2025, respectively, and $0.1 million and $2.5 million within Operating expenses for the three and nine months ended September 30, 2025, respectively.

The Company recorded restructuring charges of $0.1 million and $1.8 million during the three and nine months ended September 30, 2024, respectively, related to headcount reductions and $0.1 million and $1.1 million during the three and nine months ended September 30, 2024, respectively, for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations, all within the PD segment. The Company recorded charges of $0.1 million and $1.4 million within Gross profit for the three and nine months ended September 30, 2024, respectively, and $0.1 million and $1.5 million within Operating expenses for the three and nine months ended September 30, 2024, respectively.

The following table details restructuring charges incurred by reportable segment for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
Precision Devices	$	0.3	$	0.2	$	1.7	$	2.9
MedTech & Specialty Audio	—		—		0.3		—

Corporate	—		—		1.2		—
Total	$	0.3	$	0.2	$	3.2	$	2.9

The following table details the Company’s severance and other restructuring accrual activity:


(in millions)	Severance Pay and Benefits (1)		Contract Termination and Other Costs (2)		Total
Balance at December 31, 2024	$	0.4	$	9.4	$	9.8

Restructuring charges	3.2		—		3.2
Payments	(2.3)		(4.9)		(7.2)
Other, including foreign currency	—		0.6		0.6
Balance at September 30, 2025	$	1.3	$	5.1	$	6.4

(1) All accruals for Severance Pay and Benefits are reflected within Other accrued expenses on the Consolidated Balance Sheet.

(2) Accruals for Contract Termination and Other Costs of $5.1 million and $4.6 million were reflected within Other accrued expenses on the Consolidated Balance Sheet at September 30, 2025 and December 31, 2024, respectively. The remaining balances are reflected within Other liabilities.

The severance and restructuring accruals are recorded in the following line item on the Consolidated Balance Sheets:


(in millions)	September 30, 2025		December 31, 2024
Other accrued expenses	$	6.4	$	5.0
Other liabilities	—		4.8
Total	$	6.4	$	9.8


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

9. Borrowings

Borrowings consist of the following:


(in millions)	September 30, 2025		December 31, 2024
$400.0 million Revolving Credit Facility	$	104.0	$	134.0
Seller Note	72.3		68.5
Total	176.3		202.5
Less current maturities of Seller Note	72.3		68.5
Total long-term debt	$	104.0	$	134.0

Total debt principal payments over the next five years are as follows:


(in millions)
Q4 2025	$	72.7
2026	—
2027	—
2028	104.0
2029	—

Revolving Credit Facility

On February 8, 2023, the Company entered into an Amended and Restated Credit Agreement (the "A&R Credit Agreement") that amends and restates the prior Credit Agreement, dated September 4, 2020, and provides for a senior secured revolving credit facility with borrowings in an aggregate principal amount at any time outstanding not to exceed $400.0 million (the "Credit Facility"). The A&R Credit Agreement, among other things, extends the maturity date of the Credit Facility from January 2, 2024 to February 8, 2028, replaces the London Inter-Bank Offered Rate (“LIBOR”) with the Term Secured Overnight Financing Rate (“Term SOFR”) as a reference rate available for borrowings, amends the minimum Interest Coverage Ratio, and amends certain other financial covenants with which the Company must comply, as described below.

On September 25, 2023, the Company amended its A&R Credit Agreement to, among other things, (a) permit the Company in connection with the acquisition of Cornell Dubilier ("CD"), to incur senior priority seller financing indebtedness (the “Seller Note”) in an aggregate principal amount of $122.9 million secured by certain assets (including equity interests) acquired in connection with such acquisition and the capital stock of Cornell Dubilier, LLC (the “Acquisition Assets”), which shall mature two years after the effective date of such Seller Note (the “Seller Note Maturity Date”), (b) extends the requirement to pledge the Acquisition Assets that would otherwise constitute collateral under the Credit Agreement to the date that is 90 days after the Seller Note Maturity Date, and (c) restricts, until the Seller Note Maturity Date, the amount of dispositions and investments from the Company and certain of its subsidiaries into Cornell Dubilier, LLC and the acquired subsidiaries that constitute Acquisition Assets from exceeding $80.0 million in the aggregate. All other terms remain the same as the A&R Credit Agreement dated February 8, 2023.

Up to $100.0 million of the Credit Facility will be available in Euro, Pounds Sterling, and other currencies requested by the Company and up to $50.0 million of the Credit Facility will be made available in the form of letters of credit. Undrawn amounts under the Credit Facility accrue a commitment fee at a per annum rate of 0.225% to 0.350%, based on a leverage ratio grid.

At any time during the term of the Credit Facility, the Company may request to increase the commitments under the Credit Facility or to establish one or more incremental term loan facilities under the Credit Facility in an aggregate principal amount not to exceed the sum of $200.0 million, plus additional amounts, so long as the senior secured leverage ratio does not exceed 2.00 to 1.00.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

The A&R Credit Agreement includes requirements, to be tested quarterly, that the Company maintains (i) a minimum ratio of Consolidated EBITDA to consolidated cash interest expense of 3.00 to 1.00, (the "Interest Coverage Ratio"), (ii) a ratio of total indebtedness, minus netted cash in an aggregate amount not to exceed $50.0 million, to Consolidated EBITDA of 3.75 to 1.00 (the "Total Net Leverage Ratio"), and (iii) a maximum ratio of senior net secured indebtedness to Consolidated EBITDA of 3.25 to 1.00 (the "Senior Secured Net Leverage Ratio"). For these ratios, Consolidated EBITDA and consolidated interest expense are calculated using the most recent four consecutive fiscal quarters in a manner defined in the A&R Credit Agreement. At September 30, 2025, the Company was in compliance with these covenants and it expects to remain in compliance with all of its debt covenants over the next twelve months.

The interest rates under the Credit Facility will be, at the Borrowers' option (1) (A) in the case of borrowings denominated in U.S. dollars Term SOFR, (B) in the case of borrowings denominated in Sterling, Daily Simple Sonia, or (C) for borrowings denominated in Euro, EURIBOR, in each case, plus the rates per annum determined from time to time based on the total net leverage ratio of the Company as of the end of and for the most recent period of four fiscal quarters for which financial statements have been delivered (the "Applicable Margin"); or (2) in the case of borrowings denominated in U.S. dollars, alternate base rate ("ABR") (as defined in the A&R Credit Agreement) plus the Applicable Margin. The Applicable Margin for Term SOFR, Daily Simple Sonia, or EURIBOR could range from 1.50% to 2.50% while the Applicable Margin for ABR could range from 0.50% to 1.50%.

The weighted-average interest rate on the Company's borrowings under the Credit Facility was 6.18% and 7.24% for the nine months ended September 30, 2025 and 2024, respectively. The weighted-average commitment fee on the revolving line of credit was 0.25% and 0.26% for the nine months ended September 30, 2025 and 2024, respectively.

Seller Note

In connection with the acquisition of Cornell Dubilier on November 1, 2023, the Company obtained an interest-free Seller Note with aggregate principal payments of $122.9 million. The Company recorded the Seller Note on the acquisition date at its present value of $109.9 million by discounting the future principal payments using an imputed rate of interest of approximately 7.1% in accordance with accounting guidance in ASC 835, Interest. The Company has made a successful indemnity claim against the Seller Note of $0.2 million. The Company repaid $50.0 million of the Seller Note on November 1, 2024 and the remaining $72.7 million balance is due and payable in cash on November 1, 2025. The Company recognized imputed interest expense on the Seller Note of approximately $1.3 million and $2.0 million for the three months ended September 30, 2025 and 2024, respectively. For the nine months ended September 30, 2025 and 2024, the Company recognized imputed interest expense on the Seller Note of approximately $3.8 million and $6.0 million, respectively.

The Seller Note is secured by certain assets (including equity interest) acquired in connection with the acquisition. The Seller Note includes Knowles Capital Holdings, Inc. and Knowles Intermediate PD Holdings, LLC as borrowers, which jointly and severally agree to pay James P. Kaplan, as representative of the sellers of Cornell Dubilier, the principal amount as described above. The Seller Note is not interest-bearing except at such time as an event of default has occurred, upon which and during the continuance of an event of default, all overdue principal will accrue interest at 2.0% per annum plus the SOFR-based rate otherwise applicable under the Company’s existing credit facility. The Seller Note is subject to customary conditions and events of default and the secured nature of the Seller Note is supported by a Security Agreement.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

10. Other Comprehensive Earnings

The amounts recognized in other comprehensive (loss) earnings were as follows:


	Three Months Ended
	September 30, 2025						September 30, 2024
(in millions)	Pre-tax		Tax		Net of tax		Pre-tax		Tax		Net of tax
Foreign currency translation	$	0.4	$	—	$	0.4	$	17.1	$	—	$	17.1
Employee benefit plans	0.1		—		0.1		0.2		0.1		0.3
Changes in fair value of cash flow hedges	(0.9)		—		(0.9)		2.7		(0.4)		2.3

Total other comprehensive (loss) earnings	$	(0.4)	$	—	$	(0.4)	$	20.0	$	(0.3)	$	19.7

	Nine Months Ended
	September 30, 2025						September 30, 2024
(in millions)	Pre-tax		Tax		Net of tax		Pre-tax		Tax		Net of tax
Foreign currency translation	$	6.5	$	—	$	6.5	$	10.5	$	—	$	10.5
Employee benefit plans	0.2		0.2		0.4		0.5		0.1		0.6
Changes in fair value of cash flow hedges	2.0		—		2.0		1.2		(0.2)		1.0

Total other comprehensive earnings	$	8.7	$	0.2	$	8.9	$	12.2	$	(0.1)	$	12.1

The following tables summarize the changes in balances of each component of accumulated other comprehensive (loss) earnings, net of tax during the nine months ended September 30, 2025 and 2024:


(in millions)	Cash flow hedges		Employee benefit plans		Cumulative foreign currency translation adjustments		Total
Balance at December 31, 2024	$	(2.1)	$	(16.9)	$	(119.1)	$	(138.1)


Other comprehensive earnings, net of tax	2.0		0.4		6.5		8.9

Balance at September 30, 2025	$	(0.1)	$	(16.5)	$	(112.6)	$	(129.2)


(in millions)	Cash flow hedges		Employee benefit plans		Cumulative foreign currency translation adjustments		Total
Balance at December 31, 2023	$	(0.7)	$	(16.2)	$	(112.9)	$	(129.8)
Other comprehensive earnings, net of tax	1.0		0.6		10.5		12.1
Balance at September 30, 2024	$	0.3	$	(15.6)	$	(102.4)	$	(117.7)


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

The following tables summarize the amounts reclassified from accumulated other comprehensive loss to earnings:


		Three Months Ended September 30,
(in millions)	Statement of Earnings Line	2025		2024
Pension and post-retirement benefit plans:
Amortization or settlement of actuarial losses and prior service costs	Other expense, net	$	0.1	$	0.2
Tax	Provision for income taxes	—		0.1
Net of tax		$	0.1	$	0.3

Cash flow hedges:
Net gains reclassified into earnings	Cost of goods sold	$	(0.4)	$	(0.2)
Tax	Provision for income taxes	0.1		—
Net of tax		$	(0.3)	$	(0.2)

		Nine Months Ended September 30,
(in millions)	Statement of Earnings Line	2025		2024
Pension and post-retirement benefit plans:
Amortization or settlement of actuarial losses and prior service costs	Other expense, net	$	0.2	$	0.5
Tax	Provision for income taxes	0.2		0.1
Net of tax		$	0.4	$	0.6

Cash flow hedges:
Net losses reclassified into earnings	Cost of goods sold	$	0.1	$	1.4
Tax	Provision for income taxes	—		(0.3)
Net of tax		$	0.1	$	1.1

11. Income Taxes

Income taxes for the interim periods presented have been included in the accompanying Consolidated Financial Statements on the basis of an estimated annual effective tax rate ("ETR"). The determination of the consolidated provision for income taxes requires management to make certain judgments and estimates. Changes in the estimated level of annual pre-tax earnings or loss, tax laws, and changes resulting from tax audits can affect the overall ETR, which impacts the level of income tax expense or benefit and net income or loss. Judgments and estimates related to the Company’s projections and assumptions are inherently uncertain and therefore, actual results could differ materially from projections.

The Company's ETR from continuing operations for the three and nine months ended September 30, 2025 was 19.3% (inclusive of discrete items totaling $0.2 million of tax expense) and 26.2% (inclusive of discrete items totaling $0.1 million of tax benefit), respectively. The discrete items impacting the tax provision for the three and nine months ended September 30, 2025 were primarily attributable to stock-based compensation. Absent the discrete items, the ETR from continuing operations for the three and nine months ended September 30, 2025 was 18.4% and 26.5%, respectively. The Company's ETR from continuing operations for the three and nine months ended September 30, 2024 was 24.6% (inclusive of discrete items totaling $0.7 million of tax benefit) and 38.1% (inclusive of discrete items totaling $0.3 million of tax benefit), respectively. The discrete items impacting the tax provision for the three and nine months ended September 30, 2024 were primarily attributable to stock-based compensation and the deferred tax impact of a tax rate change. Absent the discrete items, the ETR from continuing operations for the three and nine months ended September 30, 2024 was 30.3% and 39.5%, respectively.

The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the nine months ended September 30, 2025 and 2024.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

12. Equity Incentive Program

The following table summarizes the stock-based compensation expense recognized by the Company for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
Total pre-tax stock-based compensation expense (1)	$	5.9	$	5.8	$	22.4	$	16.8
Tax benefit	0.2		0.2		3.7		2.6
Total stock-based compensation expense, net of tax	$	5.7	$	5.6	$	18.7	$	14.2

(1) Stock-based compensation shown here reflects the expense included in continuing operations. Stock-based compensation expense included in discontinued operations totaled $1.5 million and $4.6 million for the three and nine months ended September 30, 2024.

Stock Options

No stock options were granted during the nine months ended September 30, 2025 and 2024.

The following table summarizes the Company's stock option activity for the nine months ended September 30, 2025:


	Number of Shares	Weighted-Average Exercise Price		Aggregate Intrinsic Value (in millions)		Weighted-Average Remaining Contractual Term (Years)
Outstanding at December 31, 2024	1,161,337	$	17.59


Exercised (1)	(390,889)	16.96

Expired	(148,769)	18.54
Outstanding at September 30, 2025	621,679	$	17.77	$	3.4	1.5

Exercisable at September 30, 2025	621,679	$	17.77	$	3.4	1.5

(1) The number of stock options exercised includes shares that the Company withheld on behalf of employees to satisfy the option exercise price (in the instances of net exercises) as well as statutory tax withholding requirements.

There was no unrecognized compensation expense related to stock options at September 30, 2025.

RSUs

The following table summarizes the Company's restricted stock unit ("RSU") activity for the nine months ended September 30, 2025:


	Share units	Weighted-average grant date fair value
Unvested at December 31, 2024	1,819,308	$	17.79
Granted	1,047,472	18.04

Vested (1)	(836,588)	18.27
Forfeited	(96,651)	17.51
Unvested at September 30, 2025	1,933,541	$	17.73

(1) The number of RSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements.

As of September 30, 2025, the Company had $20.2 million of unrecognized compensation expense related to its RSUs that it expects to recognize over a weighted-average period of 1.6 years.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

PSUs

The Company grants performance share units (“PSUs”) to senior management. In each case, the awards will cliff vest three years following the grant date. PSUs will be settled in shares of the Company's common stock. Depending on the Company's overall performance relative to the applicable measures, the size of the PSU awards are subject to adjustment, up or down, resulting in awards at the end of the performance period that can range from 0% to 225% of target. The Company will ratably recognize the expense over the applicable service period for each grant of PSUs. The fair value of PSUs is determined by using a Monte Carlo simulation. For the awards granted in February 2025, 2024, and 2023, the number of PSUs that may be earned and vest is based on total shareholder return (“TSR”) relative to the component companies of the Russell 2000 Index over a three-year performance period.

On February 18, 2025 the Company granted a special PSU award to its Chief Executive Officer of 81,788 target PSUs with a grant date fair value of $1.5 million. This award is eligible to vest based on the achievement of a minimum non-GAAP diluted earnings per share amount and specified revenue goals over a potential five-year performance period. If the goals are not met during the initial three-year performance period, it may be extended an additional two years at a reduced payout level. Achievement could range from 0% to 400% of the target number of PSUs. The Company will ratably recognized the expense for this award over the applicable service period and adjust the expense for the expected achievement of performance conditions as necessary.

The following table summarizes the Company's PSU activity for the nine months ended September 30, 2025:


	Share units (1)	Weighted-average grant date fair value
Unvested at December 31, 2024	842,866	$	27.25
Granted	455,018	24.08

Vested (2)	(221,616)	29.92

Unvested at September 30, 2025	1,076,268	$	25.36

(1) The number of PSUs shown reflects 100% of the target award; actual payouts may differ based on performance.

(2) The number of PSUs vested includes shares that the Company withheld on behalf of employees to satisfy statutory tax withholding requirements.

As of September 30, 2025, the Company had $10.6 million of unrecognized compensation expense related to its PSUs that it expects to recognize over a weighted-average period of 1.5 years.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

13. Earnings per Share

Basic and diluted earnings per share were computed as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions, except per share amounts)	2025		2024		2025		2024
Earnings from continuing operations	$	18.0	$	9.2	$	25.4	$	13.0
Loss from discontinued operations, net	(0.6)		(8.7)		(2.2)		(269.3)
Net earnings (loss)	$	17.4	$	0.5	$	23.2	$	(256.3)

Basic earnings (loss) per common share:
Earnings from continuing operations	$	0.21	$	0.10	$	0.29	$	0.15
Loss from discontinued operations, net	(0.01)		(0.09)		(0.02)		(3.02)
Net earnings (loss)	$	0.20	$	0.01	$	0.27	$	(2.87)

Weighted-average shares outstanding	85.8		88.7		86.8		89.2

Diluted earnings (loss) per common share:
Earnings from continuing operations	$	0.21	$	0.10	$	0.29	$	0.14
Loss from discontinued operations, net	(0.01)		(0.09)		(0.03)		(2.98)
Net earnings (loss)	$	0.20	$	0.01	$	0.26	$	(2.84)

Weighted-average shares outstanding (1)	87.3		89.7		88.1		90.2

(1) In accordance with ASC 260, Earnings Per Share, the control number for determining whether including potential common shares in the diluted EPS computation would be antidilutive is earnings from continuing operations.

For both the three and nine months ended September 30, 2025, the weighted-average number of antidilutive potential common shares for stock-based awards excluded from the diluted earnings per share calculation above was 0.8 million. For the three and nine months ended September 30, 2024, the weighted-average number of antidilutive potential common shares for stock-based awards excluded from the diluted earnings per share calculation above was 0.7 million and 1.2 million, respectively.

14. Commitments and Contingent Liabilities

From time to time, the Company is involved in various legal proceedings and claims arising in the ordinary course of its business. The majority of these claims and proceedings relate to commercial, warranty, employment, and intellectual property matters. Although the ultimate outcome of any legal proceeding or claim cannot be predicted with certainty, based on present information, including management’s assessment of the merits of the particular claim, the Company believes that the disposition of these legal proceedings or claims, individually or in the aggregate, after taking into account recorded accruals and the availability and limits of insurance coverage, will not have a material adverse effect on its cash flow, results of operations, or financial condition.

The Company owns many patents and other intellectual property pertaining to its products, technology, and manufacturing processes. Some of the Company's patents have been and may continue to be infringed upon or challenged by others. In appropriate cases, the Company has taken and will take steps to protect and defend its patents and other intellectual property, including through the use of legal proceedings in various jurisdictions around the world. Such steps have resulted in and may continue to result in retaliatory legal proceedings, including litigation or other legal proceedings in various jurisdictions and forums around the world alleging infringement by the Company of patents owned by others. The costs of investigations and legal proceedings relating to the enforcement and defense of the Company’s intellectual property may be substantial. Additionally, in multi-forum disputes, the Company may incur adverse judgments with regard to certain claims in certain jurisdictions and forums while still contesting other related claims against the same opposing party in other jurisdictions and forums.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

Intellectual Property Infringement Claims

The Company may, on a limited basis, provide contractual indemnities for certain losses that arise out of claims that its products infringe on the intellectual property of others. It is not possible to determine the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Historically, the Company has not made significant payments under such indemnity arrangements. The Company’s legal accruals associated with these indemnity arrangements were not significant at September 30, 2025 and December 31, 2024.

15. Segment Information

The Company's two reportable segments are Precision Devices and MedTech & Specialty Audio. Information regarding the Company’s reportable segments is as follows:


	Three Months Ended September 30, 2025
(in millions)	Precision Devices		MedTech & Specialty Audio		Total
Revenues	$	88.2	$	64.7	$	152.9
Adjusted cost of goods sold	51.6		30.4		82.0
Adjusted research and development expenses	4.2		4.6		8.8
Adjusted selling and administrative expenses	12.0		3.5		15.5
Other segment items (1)	0.2		—		0.2
Segment adjusted earnings before interest and income taxes	$	20.2	$	26.2	$	46.4
Less:
Corporate expenses					11.9
Stock-based compensation expense					5.9
Intangibles amortization expense					4.0

Restructuring charges					0.3
Production transfer costs					0.6
Acquisition-related costs					(0.1)
Transition services credit					(0.5)
Other (2)					(0.3)
Interest expense, net					2.3
Earnings before income taxes and discontinued operations					$	22.3

(1) Other segment items primarily include foreign currency exchange gains and losses and other non-operating income and expense.

(2) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)


	Three Months Ended September 30, 2024
(in millions)	Precision Devices		MedTech & Specialty Audio		Total
Revenues	$	78.8	$	63.7	$	142.5
Adjusted cost of goods sold	47.3		29.9		77.2
Adjusted research and development expenses	4.3		4.6		8.9
Adjusted selling and administrative expenses	11.1		3.1		14.2

Segment adjusted earnings before interest and income taxes	$	16.1	$	26.1	$	42.2
Less:
Corporate expenses					12.2
Stock-based compensation expense					5.8
Intangibles amortization expense					4.2
Restructuring charges					0.2
Production transfer costs					1.4
Acquisition-related costs					1.3
Other (1)					1.0
Interest expense, net					3.9
Earnings before income taxes and discontinued operations					$	12.2

(1) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.


	Nine Months Ended September 30, 2025
(in millions)	Precision Devices		MedTech & Specialty Audio		Total
Revenues	$	239.2	$	191.8	$	431.0
Adjusted cost of goods sold	146.3		94.3		240.6
Adjusted research and development expenses	12.1		13.7		25.8
Adjusted selling and administrative expenses	35.6		10.4		46.0
Other segment items (1)	0.4		(0.2)		0.2
Segment adjusted earnings before interest and income taxes	$	44.8	$	73.6	$	118.4
Less:
Corporate expenses					34.5
Stock-based compensation expense					22.4
Intangibles amortization expense					12.1
Impairment charges					3.6
Restructuring charges					3.2
Production transfer costs					1.0
Acquisition-related costs					0.6
Transition services credit					(1.7)
Other (2)					0.8
Interest expense, net					7.5
Earnings before income taxes and discontinued operations					$	34.4

(1) Other segment items primarily include foreign currency exchange gains and losses and other non-operating income and expense.

(2) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)


	Nine Months Ended September 30, 2024
(in millions)	Precision Devices		MedTech & Specialty Audio		Total
Revenues	$	227.2	$	183.8	$	411.0
Adjusted cost of goods sold	141.3		86.0		227.3
Adjusted research and development expenses	11.9		13.3		25.2
Adjusted selling and administrative expenses	36.2		9.5		45.7
Other segment items (1)	0.1		—		0.1
Segment adjusted earnings before interest and income taxes	$	37.7	$	75.0	$	112.7
Less:
Corporate expenses					34.2
Stock-based compensation expense					16.8
Intangibles amortization expense					12.8
Restructuring charges					2.9
Production transfer costs					3.0
Acquisition-related costs					7.5
Other (2)					1.6
Interest expense, net					12.9
Earnings before income taxes and discontinued operations					$	21.0

(1) Other segment items primarily include foreign currency exchange gains and losses and other non-operating income and expense.

(2) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.

Information regarding assets of the Company's reportable segments is as follows:


	Total Assets
(in millions)	September 30, 2025		December 31, 2024
Precision Devices	$	584.2	$	619.9
MedTech & Specialty Audio	413.9		410.6

Corporate (1)	90.1		87.7

Total	$	1,088.2	$	1,118.2

(1) Corporate assets at both September 30, 2025 and December 31, 2024 include $77.2 million of Syntiant preferred stock received in partial consideration for the sale of CMM on December 27, 2024 and a note receivable from Syntiant totaling $5.9 million and $6.4 million at September 30, 2025 and December 31, 2024, respectively. Corporate assets also include the portion of right-of-use operating lease assets subleased by Syntiant, which totaled $5.2 million and $0.3 million at September 30, 2025 and December 31, 2024, respectively.

The following table details revenues by geographic location. Revenues are attributed to regions based on the location of the Company's direct customer, which in some instances is an intermediary and not necessarily the end user. The Company's businesses are based primarily in Asia, North America, and Europe.


	Three Months Ended September 30,				Nine Months Ended September 30,
(in millions)	2025		2024		2025		2024
United States	$	66.8	$	62.3	$	180.8	$	178.6
Asia	56.7		50.1		163.2		135.9
Europe	23.9		23.5		72.1		76.6
Other Americas	3.2		3.5		8.1		8.6
Other	2.3		3.1		6.8		11.3
Total	$	152.9	$	142.5	$	431.0	$	411.0


Table of Contents			NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
			(unaudited)

Receivables, net from contracts with customers were $93.5 million and $89.5 million as of September 30, 2025 and December 31, 2024, respectively. As of September 30, 2025 and December 31, 2024, our total remaining performance obligations were immaterial.

Table of Contents

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to our operations, results of operations, our continued business operations, and other matters that are based on our current expectations, estimates, assumptions, and projections. Words such as “believe,” “expect,” “anticipate,” “project,” “estimate,” “budget,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “seek,” “should,” “will,” “would,” “objective,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” and similar expressions, among others, generally identify forward-looking statements, which speak only as of the date the statements were made. The statements in this Quarterly Report on Form 10-Q are based on currently available information and the current expectations, forecasts, and assumptions of our management concerning risks and uncertainties that could cause actual outcomes or results to differ materially from those outcomes or results that are projected, anticipated, or implied in these statements. Other risks and uncertainties include, but are not limited to:


o			our ability to achieve some or all of the strategic and financial benefits that we expect to achieve in connection with our CMM divestiture;
o			difficulties or delays in and/or the Company's inability to realize expected synergies from its acquisitions;
o			fluctuations in our stock's market price;
o			fluctuations in operating results and cash flows;
o			our ability to prevent or identify quality issues in our products or to promptly remedy any such issues that are identified;
o			risks associated with increasing our inventories in advance of anticipated orders by customers;
o			global economic instability, including due to inflation, rising interest rates, negative impacts caused by pandemics and public health crises, or the impacts of geopolitical uncertainties;
o			the impact of changes to laws and regulations that affect the Company’s ability to offer products or services to customers in different regions;
o			our ability to achieve reductions in our operating expenses;
o			the ability to qualify our products and facilities with customers;
o			our ability to obtain, enforce, defend, or monetize our intellectual property rights;
o			disruption caused by a cybersecurity incident, including a cyber attack, cyber breach, theft, or other unauthorized access;
o			increases in the costs of critical raw materials and components;
o			availability of raw materials and components;
o			managing new product ramps and introductions for our customers;
o			our dependence on a limited number of large customers;
o			our ability to maintain and expand our existing relationships with leading OEMs in order to maintain and increase our revenue;
o			increasing competition and new entrants in the market for our products;
o			our ability to develop new or enhanced products or technologies in a timely manner that achieve market acceptance;
o			escalating international trade tensions, new or increased tariffs, and trade wars among countries;
o			financial risks, including risks relating to currency fluctuations, credit risks, and fluctuations in the market value of the Company;
o			a sustained decline in our stock price and market capitalization may result in the impairment of certain intangible or long-lived assets;
o			market risk associated with fluctuations in commodity prices, particularly for various precious metals used in our manufacturing operation,
o			changes in tax laws, changes in tax rates, and exposure to additional tax liabilities.

A more complete description of these risks, uncertainties, and other factors can be found under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024. We do not undertake to update or revise our forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with our Consolidated Financial Statements and related Notes included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are a leading manufacturer of specialty electronic components. We design parts that perform unique and critical functions for innovative technologies. Through extreme reliability, custom engineering, and scalable manufacturing, we enable businesses to succeed in the most demanding applications across medtech, defense, industrial, and electrification markets. Our high performance capacitors, radio frequency ("RF") and microwave filters, advanced medtech microphones, and balanced armature speakers, enhance the performance of our customers products to change, improve, and save lives. Our focus on the customer, combined with unique technology, proprietary manufacturing techniques, and global operational expertise, enables us to deliver innovative solutions across multiple applications. References to "Knowles," the "Company," "we," "our," or "us" refer to Knowles Corporation and its consolidated subsidiaries, unless the context otherwise requires.

We sell our products directly to original equipment manufacturers ("OEMs") and to their contract manufacturers and suppliers and through distributors worldwide.

Recent Developments

On April 2, 2025, the U.S. announced a new universal baseline tariff of 10%, plus an additional country-specific tariff for select trading partners, on all U.S. imports. These actions, and retaliatory tariffs imposed by foreign jurisdictions, have resulted in market volatility and uncertainty regarding the ultimate effect of the tariffs on global economic conditions. We do not anticipate that these factors will have a material impact on our operations; however, we continue to monitor changes in international trade relations and trade policy, including those related to tariffs, which could adversely impact our results. We are optimizing operations and leveraging existing programs and strategies to reduce the impact from tariffs. Additionally, we are taking measures to control costs and implementing pricing actions designed to mitigate the risk these policies may have on our revenues and operations.

On December 27, 2024, the Company consummated the sale and assignment of certain assets and liabilities of the Company’s Consumer MEMS Microphones ("CMM") segment to Syntiant Corp. ("Syntiant") for approximately $150.0 million in total consideration, consisting of $70.0 million cash ($58.0 million in net cash received) as adjusted for agreed deductions for indebtedness, and working capital and $80.0 million in Syntiant Series D-2 preferred stock (with a fair value of $77.2 million), par value $0.0001. The Company provided $6.4 million in financing, which was utilized to fund Syntiant's requirement to have $40.0 million of cash on its balance sheet at closing. The Company will also share in certain separation costs pursuant to a credit, which Syntiant may apply to specified separation costs post-closing. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements under Part I, Item 1, "Financial Statements."

We have reclassified the results of operations and financial position of CMM to discontinued operations for all periods presented. Unless otherwise noted, our results of operations discussed below relate to continuing operations and will be impacted by the CMM divestiture.

This divestiture supports Knowles' continued transformation into an industrial technology company, consisting of its Precision Devices ("PD") and MedTech & Specialty Audio ("MSA") segments, primarily serving the defense, medtech, industrial, and electrification markets. We have incurred some amount of dis-synergies following the sale of CMM due to the reduced size of our company and, as a result, we have undertaken actions to help ensure that our cost structure is appropriate to support our remaining businesses.

As inventory levels in the industrial markets have recently begun to normalize, our Precision Devices segment has experienced increased bookings for the past four quarters. In addition, with bookings increasing we have seen backlog across our capacitor products increase for the past four quarters.

Non-GAAP Financial Measures

In addition to the GAAP financial measures included in this item, we have presented certain non-GAAP financial measures. We use non-GAAP measures as supplements to our GAAP results of operations in evaluating certain aspects of our business, and our executive management team and Board of Directors focus on non-GAAP items as key measures of our performance for business planning purposes. These measures assist us in comparing our performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in our opinion, do not reflect our core operating performance. We believe that our presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that we use internally for purposes of assessing our core operating performance. The Company does not consider these non-GAAP financial measures to be a substitute for the information provided by GAAP financial results. For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures, see the reconciliation included herein.

Table of Contents

Results of Operations for the Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024


	Three Months Ended September 30,
(in millions, except per share amounts)	2025		2024
Revenues	$	152.9	$	142.5

Gross profit	$	69.9	$	62.9
Non-GAAP gross profit	$	70.7	$	64.8

Earnings from continuing operations before interest and income taxes	$	24.6	$	16.1

Adjusted earnings from continuing operations before interest and income taxes	$	34.5	$	30.0

Provision for income taxes	$	4.3	$	3.0
Non-GAAP provision for income taxes	$	3.3	$	1.9

Net earnings from continuing operations	$	18.0	$	9.2
Non-GAAP net earnings from continuing operations	$	28.9	$	24.2

Earnings per share from continuing operations - diluted	$	0.21	$	0.10
Non-GAAP diluted earnings per share	$	0.33	$	0.27

Revenues

Revenues for the third quarter of 2025 were $152.9 million, compared with $142.5 million for the third quarter of 2024, an increase of $10.4 million or 7.3%. PD revenues increased $9.4 million due to higher demand in the defense, electrification, medtech, and industrial markets, as well as higher average pricing. MSA revenues increased $1.0 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and higher shipping volumes into the specialty audio market, partially offset by lower shipping volumes into the hearing health market.

Cost of Goods Sold

Cost of goods sold ("COGS") for the third quarter of 2025 was $82.8 million, compared with $79.5 million for the third quarter of 2024, an increase of $3.3 million or 4.2%. This increase was primarily due to higher shipping volumes, unfavorable product mix, and lower than expected yields in our CD business as we ramp up our specialty film product line, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, favorable inventory reserve adjustments, a reduction of CD related production transfer costs, and lower precious metal costs.

Restructuring Charges

During the third quarter of 2025, we recorded restructuring charges of $0.3 million related primarily to headcount reductions across the Company to rightsize expenses subsequent to the sale of CMM. During the third quarter of 2024, we recorded restructuring charges of $0.2 million for headcount reductions and costs to transfer certain capacitors manufacturing to existing facilities to further optimize operations. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.

Table of Contents

Gross Profit and Non-GAAP Gross Profit

Gross profit for the third quarter of 2025 was $69.9 million, compared with $62.9 million for the third quarter of 2024, an increase of $7.0 million or 11.1%. Gross profit margin (gross profit as a percentage of revenues) for the third quarter of 2025 was 45.7%, compared with 44.1% for the third quarter of 2024. The increases in gross profit and gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.

Non-GAAP gross profit for the third quarter of 2025 was $70.7 million, compared with $64.8 million for the third quarter of 2024, an increase of $5.9 million or 9.1%. Non-GAAP gross profit margin (non-GAAP gross profit as a percentage of revenues) for the third quarter of 2025 was 46.2% compared with 45.5% for the third quarter of 2024. The increases in non-GAAP gross profit and non-GAAP gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.

Research and Development Expenses

Research and development expenses for the third quarter of 2025 were $10.0 million, compared with $10.2 million for the third quarter of 2024, a decrease of $0.2 million or 2.0%. Research and development expenses as a percentage of revenues for the third quarter of 2025 and 2024 were 6.5% and 7.2%, respectively. The decreases in expenses were primarily driven by the timing of some development activities. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Selling and Administrative Expenses

Selling and administrative expenses for the third quarter of 2025 were $34.0 million, compared with $33.9 million for the third quarter of 2024, an increase of $0.1 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the third quarter of 2025 and 2024 were 22.2% and 23.8%, respectively. The increase in expenses was primarily driven by higher incentive compensation, partially offset by a reduction of CD related acquisition costs and the benefits of restructuring actions. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Interest Expense, net

Interest expense for the third quarter of 2025 was $2.3 million, compared with $3.9 million for the third quarter of 2024, a decrease of $1.6 million. The decrease is due to a lower outstanding revolving credit facility balance during the third quarter of 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 9. Borrowings to our Consolidated Financial Statements.

Other Expense, net

Other expense for the third quarter of 2025 was $1.2 million, compared with expense of $2.6 million for the third quarter of 2024, a change of $1.4 million. Expense in both 2025 and 2024 is primarily due to unfavorable foreign currency exchange rate changes.

Provision for Income Taxes and Non-GAAP Provision for Income Taxes

Effective tax rate ("ETR") for the third quarter of 2025 and 2024 was 19.3% and 24.6%, respectively. The ETR for the third quarter of 2025 and 2024 includes discrete items totaling $0.2 million of tax expense and $0.7 million of tax benefit, respectively. The discrete items impacting the tax provision for 2025 and 2024 are primarily attributable to stock-based compensation and the deferred tax impact of a tax rate change. Absent the discrete items, the ETR for the third quarter of 2025 and 2024 was 18.4% and 30.3%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provisions for the third quarter of 2025 and 2024, respectively. The change in the ETR was due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

Table of Contents

Non-GAAP ETR for the third quarter of 2025 and 2024 was 10.2% and 7.3%, respectively. The non-GAAP ETR includes discrete items totaling $0.1 million of tax expense and $0.9 million of tax benefit for the three months ended September 30, 2025 and 2024, respectively. Absent the discrete items, the non-GAAP ETR for the third quarter of 2025 and 2024 was 9.9% and 10.7%, respectively. The change in the non-GAAP ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

On July 4, 2025, the One Big Beautiful Bill Act was signed into U.S. federal law. Based on our analysis of the law, we do not anticipate the One Big Beautiful Bill Act having a material impact on the financial statements of Knowles in 2025 or subsequent years.

Earnings from Continuing Operations

Earnings from continuing operations for the third quarter of 2025 was $18.0 million, compared with $9.2 million for the third quarter of 2024, an improvement of $8.8 million. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher income tax expense.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

Earnings from continuing operations before interest and income taxes ("EBIT") for the third quarter of 2025 was $24.6 million, compared with $16.1 million for the third quarter of 2024, an increase of $8.5 million. EBIT margin (EBIT as a percentage of revenues) for the third quarter of 2025 was 16.1%, compared with 11.3% for the third quarter of 2024. The increase in EBIT and EBIT margin was primarily due to higher gross profit.

Adjusted earnings before interest and income taxes ("Adjusted EBIT") from continuing operations for the third quarter of 2025 was $34.5 million, compared with $30.0 million for the third quarter of 2024, an increase of $4.5 million. Adjusted EBIT margin (Adjusted EBIT from continuing operations as a percentage of revenues) for the third quarter of 2025 was 22.6%, compared with 21.1% for the third quarter of 2024. The increase in Adjusted EBIT and Adjusted EBIT margin was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses.

Loss from Discontinued Operations, net

We recorded a loss of $0.6 million for the third quarter of 2025, primarily driven by a change in tax expense. We recorded a loss of $8.7 million for the third quarter of 2024, primarily driven by our goodwill impairment and loss on disposal of business related to the divestiture of CMM, partially offset by favorable income tax changes. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.

Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations

Diluted earnings per share from continuing operations was $0.21 for the third quarter of 2025, compared with $0.10 for the third quarter of 2024, an improvement of $0.11. As described above, the improvement is primarily due to higher gross profit, lower interest expense and reduced share count, partially offset by higher income tax expense.

Non-GAAP diluted earnings per share from continuing operations was $0.33 for the third quarter of 2025, compared with $0.27 for the third quarter of 2024, an improvement of $0.06. As described above, the improvement is primarily due to higher non-GAAP gross profit, lower interest expense, and reduced share count, partially offset by higher non-GAAP operating expenses and higher non-GAAP income tax expense.

Table of Contents

Results of Operations for the Nine Months Ended September 30, 2025 compared with the Nine Months Ended September 30, 2024


	Nine Months Ended September 30,
(in millions, except per share amounts)	2025		2024
Revenues	$	431.0	$	411.0

Gross profit	$	183.8	$	173.9
Non-GAAP gross profit	$	190.2	$	182.5

Earnings from continuing operations before interest and income taxes	$	41.9	$	33.9

Adjusted earnings from continuing operations before interest and income taxes	$	83.9	$	78.5

Provision for income taxes	$	9.0	$	8.0
Non-GAAP provision for income taxes	$	10.1	$	6.0

Net earnings from continuing operations	$	25.4	$	13.0
Non-GAAP net earnings from continuing operations	$	66.3	$	59.6

Earnings per share from continuing operations - diluted	$	0.29	$	0.14
Non-GAAP diluted earnings per share	$	0.75	$	0.65

Revenues

Revenues for the nine months ended September 30, 2025 were $431.0 million, compared with $411.0 million for the nine months ended September 30, 2024, an increase of $20.0 million or 4.9%. PD revenues increased $12.0 million due to higher demand from the medtech, electrification, and defense markets, as well as higher average pricing, partially offset by lower demand from the industrial market. MSA revenues increased $8.0 million, primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio market, partially offset by lower average pricing on mature products and lower shipping volumes into the hearing health market.

Cost of Goods Sold

COGS for the nine months ended September 30, 2025 was $242.9 million, compared with $235.7 million for the nine months ended September 30, 2024, an increase of $7.2 million or 3.1%. This increase was primarily due to higher shipping volumes, unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, a reduction of CD related acquisition and production transfer costs, and lower precious metal costs.

Impairment Charges

During the nine months ended September 30, 2025, we recorded an impairment charge of $3.6 million to write down the carrying value of certain machinery and equipment to fair value. For additional information, refer to Note 1. Basis of Presentation to our Consolidated Financial Statements.

Table of Contents

Restructuring Charges

During the nine months ended September 30, 2025, we recorded restructuring charges of $0.7 million within Gross profit and $2.5 million within Operating expenses primarily related to headcount reductions across the Company to rightsize operating expenses subsequent to the sale of CMM. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.

During the nine months ended September 30, 2024, we recorded restructuring charges of $1.8 million related to headcount reductions and $1.1 million for costs associated with transferring certain capacitors manufacturing to existing facilities to further optimize operations within our PD segment. These actions resulted in restructuring charges of $1.4 million within Gross profit and $1.5 million within Operating expenses. For additional information, refer to Note 8. Restructuring and Related Activities to our Consolidated Financial Statements.

Gross Profit and Non-GAAP Gross Profit

Gross profit for the nine months ended September 30, 2025 was $183.8 million, compared with $173.9 million for the nine months ended September 30, 2024, an increase of $9.9 million or 5.7%. Gross profit margin for the nine months ended September 30, 2025 was 42.6%, compared with 42.3% for the nine months ended September 30, 2024. The increases in gross profit and gross profit margin were primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, a reduction of CD related acquisition and production transfer costs, lower precious metal costs and restructuring charges, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on mature products in the MSA business, impairment charges in 2025, and unfavorable inventory reserve adjustments.

Non-GAAP gross profit for the nine months ended September 30, 2025 was $190.2 million, compared with $182.5 million for the nine months ended September 30, 2024, an increase of $7.7 million or 4.2%. Non-GAAP gross profit margin for the nine months ended September 30, 2025 was 44.1%, compared with 44.4% for the nine months ended September 30, 2024. The increase in non-GAAP gross profit was primarily due to higher shipping volumes, company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, and lower precious metal costs, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on mature products in the MSA business, and unfavorable inventory reserve adjustments. The decrease in non-GAAP gross profit margin is primarily due to unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, lower average pricing on our mature products in the MSA business, and unfavorable inventory reserve adjustments, partially offset by company-wide product cost reductions, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, and lower precious metals costs.

Research and Development Expenses

Research and development expenses for the nine months ended September 30, 2025 were $29.7 million, compared with $29.2 million for the nine months ended September 30, 2024, an increase of $0.5 million or 1.7%. Research and development expenses as a percentage of revenues for the nine months ended September 30, 2025 and 2024 were 6.9% and 7.1%, respectively. The increase in expenses was primarily driven by increased development activities as we continue to invest in our businesses. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Selling and Administrative Expenses

Selling and administrative expenses for the nine months ended September 30, 2025 were $107.1 million, compared with $106.8 million for the nine months ended September 30, 2024, an increase of $0.3 million or 0.3%. Selling and administrative expenses as a percentage of revenues for the nine months ended September 30, 2025 and 2024 were 24.8% and 26.0%, respectively. The increase in expenses was primarily driven by the acceleration of stock-based compensation expense for employees who are nearing or have reached retirement eligibility and higher incentive compensation, partially offset by a reduction of CD related acquisition costs, the benefits of restructuring actions, and reduced intangible amortization costs. The decrease in expenses as a percentage of revenues was driven by higher revenues.

Table of Contents

Interest Expense, net

Interest expense for the nine months ended September 30, 2025 was $7.5 million, compared with $12.9 million for the nine months ended September 30, 2024, a decrease of $5.4 million. The decrease is due to a lower outstanding revolving credit facility balance during the nine months ended September 30, 2025 and lower imputed interest expense on our Seller Note from the CD acquisition. For additional information on borrowings and interest expense, refer to Note 9. Borrowings to our Consolidated Financial Statements.

Other Expense, net

Other expense for the nine months ended September 30, 2025 was $2.6 million, compared with expense of $2.5 million for the nine months ended September 30, 2024, a change of $0.1 million. The change is primarily due to unfavorable foreign currency exchange rate changes.

Provision for Income Taxes and Non-GAAP Provision for Income Taxes

ETR for the nine months ended September 30, 2025 and 2024 was 26.2% and 38.1%, respectively. The ETR for the nine months ended September 30, 2025 and 2024 includes discrete items totaling $0.1 million and $0.3 million of tax benefit, respectively. The discrete items impacting the tax provision for the nine months ended September 30, 2024 are primarily attributable to stock-based compensation and the deferred tax impact of a tax rate change. Absent the discrete items, the ETR for the nine months ended September 30, 2025 and 2024 was 26.5% and 39.5%, respectively. The Company accrues taxes in various countries where it generates income and applies a valuation allowance in other jurisdictions, which resulted in the provision for the nine months ended September 30, 2025 and 2024. The change in the ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

Non-GAAP ETR for the nine months ended September 30, 2025 and 2024 was 13.2% and 9.1%, respectively. The non-GAAP ETR includes discrete items totaling $0.1 million of tax expense and $0.9 million of tax benefit for the nine months ended September 30, 2025 and 2024, respectively. Absent the discrete items, the non-GAAP ETR for the nine months ended September 30, 2025 and 2024 was 13.1% and 10.5%, respectively. The change in the non-GAAP ETR was mainly due to the mix of earnings and losses by taxing jurisdictions and net discrete items.

Earnings from Continuing Operations

Earnings from continuing operations for the nine months ended September 30, 2025 was $25.4 million, compared with $13.0 million for the nine months ended September 30, 2024, an improvement of $12.4 million. As described above, the improvement is primarily due to higher gross profit and lower interest expense, partially offset by higher operating expenses and income tax expense.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

EBIT for the nine months ended September 30, 2025 was $41.9 million, compared with $33.9 million for the nine months ended September 30, 2024, an increase of $8.0 million. EBIT margin for the nine months ended September 30, 2025 was 9.7%, compared with 8.2% for the nine months ended September 30, 2024. The increase in EBIT and EBIT margin was primarily due to higher gross profit, partially offset by higher operating expenses.

Adjusted EBIT from continuing operations for the nine months ended September 30, 2025 was $83.9 million, compared with $78.5 million for the nine months ended September 30, 2024, an increase of $5.4 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 19.5%, compared with 19.1% for the nine months ended September 30, 2024. The increase in Adjusted EBIT and Adjusted EBIT margin was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses.

Table of Contents

Loss from Discontinued Operations, net

Loss from discontinued operations for the nine months ended September 30, 2025 was $2.2 million, compared with a loss of $269.3 million for the nine months ended September 30, 2024. Loss from discontinued operations for the nine months ended September 30, 2025 was primarily driven by an unfavorable working capital adjustment and tax expense. Loss from discontinued operations for the nine months ended September 30, 2024 was primarily driven by goodwill impairment and loss on disposal of business related to the divestiture of CMM, partially offset by favorable income tax changes. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements.

Diluted Earnings per Share from Continuing Operations and Non-GAAP Diluted Earnings per Share from Continuing Operations

Diluted earnings per share from continuing operations was $0.29 for the nine months ended September 30, 2025, compared with $0.14 for the nine months ended September 30, 2024, an improvement of $0.15. As described above, the improvement is primarily due to higher gross profit, lower interest expense and reduced share count, partially offset by by higher operating expenses and income tax expense.

Non-GAAP diluted earnings per share from continuing operations was $0.75 for the nine months ended September 30, 2025 and $0.65 for the nine months ended September 30, 2024, an improvement of $0.10. As described above, the improvement is primarily due to higher non-GAAP gross profit, lower interest expense, and reduced share count, partially offset by higher non-GAAP income tax expense and non-GAAP operating expenses.

Table of Contents

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (1)


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(in millions, except per share amounts)	2025		2024		2025		2024
Gross profit	$	69.9	$	62.9	$	183.8	$	173.9
Stock-based compensation expense	0.3		0.3		1.1		1.1
Impairment charges	—		—		3.6		—
Restructuring charges	0.2		0.1		0.7		1.4
Production transfer costs (2)	0.6		1.3		0.9		2.8
Acquisition-related costs (3)	—		0.2		—		2.2
Transition services credit (4)	(0.3)		—		(0.7)		—
Other (5)	—		—		0.8		1.1
Non-GAAP gross profit	$	70.7	$	64.8	$	190.2	$	182.5





















Net earnings from continuing operations	$	18.0	$	9.2	$	25.4	$	13.0
Interest expense, net	2.3		3.9		7.5		12.9
Provision for income taxes	4.3		3.0		9.0		8.0
Earnings from continuing operations before interest and income taxes	24.6		16.1		41.9		33.9
Stock-based compensation expense	5.9		5.8		22.4		16.8
Intangibles amortization expense	4.0		4.2		12.1		12.8
Impairment charges	—		—		3.6		—
Restructuring charges	0.3		0.2		3.2		2.9
Production transfer costs (2)	0.6		1.4		1.0		3.0
Acquisition-related costs (3)	(0.1)		1.3		0.6		7.5
Transition services credit (4)	(0.5)		—		(1.7)		—

Other (5)	(0.3)		1.0		0.8		1.6
Adjusted earnings from continuing operations before interest and income taxes	$	34.5	$	30.0	$	83.9	$	78.5





Provision for income taxes	$	4.3	$	3.0	$	9.0	$	8.0
Income tax effects of non-GAAP reconciling adjustments (6)	(1.0)		(1.1)		1.1		(2.0)
Non-GAAP provision for income taxes	$	3.3	$	1.9	$	10.1	$	6.0

Net earnings from continuing operations	$	18.0	$	9.2	$	25.4	$	13.0
Non-GAAP reconciling adjustments (7)	9.9		13.9		42.0		44.6

Income tax effects of non-GAAP reconciling adjustments (6)	(1.0)		(1.1)		1.1		(2.0)
Non-GAAP net earnings	$	28.9	$	24.2	$	66.3	$	59.6

Diluted earnings per share from continuing operations	$	0.21	$	0.10	$	0.29	$	0.14
Earnings per share non-GAAP reconciling adjustment (6) (7) (8)	0.12		0.17		0.46		0.51
Non-GAAP diluted earnings per share (8)	$	0.33	$	0.27	$	0.75	$	0.65



Diluted average shares outstanding	87.3		89.7		88.1		90.2
Non-GAAP adjustment (8) (9)	0.6		1.6		0.7		1.5
Non-GAAP diluted average shares outstanding (8) (9)	87.9		91.3		88.8		91.7

Table of Contents

(1) In addition to the GAAP financial measures included herein, Knowles has presented certain non-GAAP financial measures that exclude certain amounts that are included in the most directly comparable GAAP measures. Knowles believes that non-GAAP measures are useful as supplements to its GAAP results of operations to evaluate certain aspects of its operations and financial performance, and its management team primarily focuses on non-GAAP items in evaluating Knowles' performance for business planning purposes. Knowles also believes that these measures assist it with comparing its performance between various reporting periods on a consistent basis, as these measures remove from operating results the impact of items that, in Knowles' opinion, do not reflect its core operating performance. Knowles believes that its presentation of non-GAAP financial measures is useful because it provides investors and securities analysts with the same information that Knowles uses internally for purposes of assessing its core operating performance.

(2) Production transfer costs represent duplicate costs incurred to migrate manufacturing to existing facilities. These amounts are included in the corresponding Gross profit and Earnings from continuing operations before interest and income taxes for each period presented.

(3) These expenses are related to the acquisition of CD by the PD segment. These expenses include ongoing costs to facilitate integration, the amortization of fair value adjustments to inventory, and costs incurred by the Company to carry out this transaction.

(4) Transition services represent amounts charged to Syntiant in connection with post-closing transition and separation costs.

(5) Other expenses include non-recurring professional service fees related to the execution of various reorganization projects and foreign currency exchange rate impacts on restructuring balances.

(6) Income tax effects of non-GAAP reconciling adjustments are calculated using the applicable tax rates in the jurisdictions of the underlying adjustments.

(7) The non-GAAP reconciling adjustments include stock-based compensation expense, intangibles amortization expense, restructuring charges, production transfer costs, acquisition-related costs, and other expenses, partially offset by a credit to transition services.

(8) In the third quarter of 2025, the Company modified its calculation method of Non-GAAP diluted average shares outstanding to exclude the potential dilution impact from performance share units ("PSUs") as these equity awards have not yet been earned. Our PSUs are market-based awards and have fluctuated based on the Company's total shareholder return performance relative to the Russell 2000 during the measurement period. The calculation methodology change in Non-GAAP diluted average shares outstanding increased Non-GAAP diluted earnings per share by $0.01 for both the three months ended September 30, 2025 and 2024, $0.02 for the nine months ended September 30, 2025, and $0.01 for the nine months ended September 30, 2024.

(9) The number of shares used in the diluted average shares outstanding calculations on a non-GAAP basis excludes the impact of stock-based compensation expense expected to be incurred in future periods and not yet recognized in the financial statements, which would otherwise be assumed to be used to repurchase shares under the GAAP treasury stock method. Non-GAAP diluted average shares outstanding also excludes the impact of certain equity awards that are not yet earned.

Table of Contents

Segment Results of Operations for the Three Months Ended September 30, 2025 compared with the Three Months Ended September 30, 2024

The following is a summary of the results of operations of our two reportable segments: Precision Devices and Medtech & Specialty Audio.

See Note 15. Segment Information to the Consolidated Financial Statements for (i) a reconciliation of segment revenues to our consolidated revenues and (ii) a reconciliation of segment adjusted earnings before interest and income taxes to our consolidated earnings before income taxes and discontinued operations.

Precision Devices


	Three Months Ended September 30,
(in millions)	2025		Percent of Revenues	2024		Percent of Revenues
Revenues	$	88.2		$	78.8



Earnings from continuing operations before interest and income taxes	$	14.3	16.2%	$	8.4	10.7%
Stock-based compensation expense	1.1			0.7
Intangibles amortization expense	4.0			4.2

Restructuring charges	0.3			0.2
Production transfer costs (1)	0.6			1.4
Acquisition-related costs (2)	(0.1)			1.2

Adjusted earnings from continuing operations before interest and income taxes	$	20.2	22.9%	$	16.1	20.4%
(1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities.
(2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration.

Revenues

PD revenues were $88.2 million for the third quarter of 2025, compared with $78.8 million for the third quarter of 2024, an increase of $9.4 million or 11.9%. Revenues increased due to higher demand in the defense, electrification, medtech, and industrial markets, as well as higher average pricing.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

PD EBIT was $14.3 million for the third quarter of 2025, compared with $8.4 million for the third quarter of 2024, an increase of $5.9 million. EBIT margin for the third quarter of 2025 was 16.2%, compared to 10.7% for the third quarter of 2024. The increases were due to higher gross profit primarily driven by higher shipping volumes, product cost reductions and increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.

PD Adjusted EBIT was $20.2 million for the third quarter of 2025, compared with $16.1 million for the third quarter of 2024, an increase of $4.1 million. Adjusted EBIT margin for the third quarter of 2025 was 22.9%, compared with 20.4% for the third quarter of 2024. The increases were due to higher non-GAAP gross profit. The non-GAAP gross profit increase was driven by higher shipping volumes, product cost reductions and increased factory capacity utilization in our ceramic capacitor and RF filter businesses, partially offset by unfavorable product mix and lower than expected yields in our CD business as we ramp up our specialty film product line.

Table of Contents

MedTech & Specialty Audio


	Three Months Ended September 30,
(in millions)	2025		Percent of Revenues	2024		Percent of Revenues
Revenues	$	64.7		$	63.7





Earnings from continuing operations before interest and income taxes	$	25.0	38.6%	$	25.0	39.2%
Stock-based compensation expense	1.2			1.1






Adjusted earnings from continuing operations before interest and income taxes	$	26.2	40.5%	$	26.1	41.0%

Revenues

MSA revenues were $64.7 million for the third quarter of 2025, compared with $63.7 million for the third quarter of 2024, an increase of $1.0 million or 1.6%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and higher shipping volumes into the specialty audio market, partially offset by lower shipping volumes into the hearing health market.

Earnings and Adjusted Earnings from Continuing Operations Before Interest and Income Taxes

MSA EBIT was $25.0 million for both the third quarter of 2025 and the third quarter of 2024. EBIT margin for the third quarter of 2025 was 38.6%, compared with 39.2% for the third quarter of 2024. The EBIT margin decrease is primarily due to unfavorable product mix and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by product cost reductions.

MSA Adjusted EBIT was $26.2 million for the third quarter of 2025, compared with $26.1 million for the third quarter of 2024, an increase of $0.1 million. Adjusted EBIT margin for the third quarter of 2025 was 40.5%, compared to 41.0% for the third quarter of 2024. The increase in adjusted EBIT was primarily due to higher non-GAAP gross profit, partially offset by higher non-GAAP operating expenses. Higher non-GAAP gross profit was driven by product cost reductions and higher shipping volumes, partially offset by unfavorable product mix. The decrease in Adjusted EBIT margin was primarily due to unfavorable product mix and the impact of higher shipping volumes of our lower margin metal can products to Syntiant.

Table of Contents

Segment Results of Operations for the Nine Months Ended September 30, 2025 compared with the Nine Months Ended September 30, 2024

Precision Devices


	Nine Months Ended September 30,
(in millions)	2025		Percent of Revenues	2024		Percent of Revenues
Revenues	$	239.2		$	227.2



Earnings before interest and income taxes	$	25.7	10.7%	$	10.5	4.6%
Stock-based compensation expense	3.7			1.5
Intangibles amortization expense	12.1			12.8

Restructuring charges	1.7			2.9
Production transfer costs (1)	1.0			3.0
Acquisition-related costs (2)	0.6			6.5
Other	—			0.5
Adjusted earnings before interest and income taxes	$	44.8	18.7%	$	37.7	16.6%
(1) Production transfer costs represent costs incurred to migrate manufacturing to existing facilities.
(2) These expenses are related to the acquisition of CD. These expenses include ongoing costs to facilitate integration and the amortization of fair value adjustments to inventory.

Revenues

PD revenues were $239.2 million for the nine months ended September 30, 2025, compared with $227.2 million for the nine months ended September 30, 2024, an increase of $12.0 million or 5.3%. Revenues increased due to higher demand from the medtech, electrification, and defense markets, as well as higher average pricing, partially offset by lower demand from the industrial market.

Earnings and Adjusted Earnings Before Interest and Income Taxes

PD EBIT was $25.7 million for the nine months ended September 30, 2025, compared with $10.5 million for the nine months ended September 30, 2024, an increase of $15.2 million. EBIT margin for the nine months ended September 30, 2025 was 10.7%, compared to 4.6% for nine months ended September 30, 2024. The increases were primarily due to higher gross profit and lower operating expenses. The gross profit increase was primarily driven by product cost reductions, higher shipping volumes, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, lower CD related acquisition and production transfer costs, higher average pricing, lower precious metal costs, and reduced restructuring charges, partially offset by lower than expected yields in our CD business as we ramp up our specialty film product line, unfavorable product mix, and unfavorable inventory reserve adjustments. The decrease in operating expenses was primarily driven by a reduction of CD acquisition related costs, the benefits of restructuring actions, and lower intangible amortization costs, partially offset by higher stock-based compensation.

PD Adjusted EBIT was $44.8 million for the nine months ended September 30, 2025, compared with $37.7 million for the nine months ended September 30, 2024, an increase of $7.1 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 18.7%, compared with 16.6% for the nine months ended September 30, 2024. The increases were primarily due to higher non-GAAP gross profit and lower non-GAAP operating expenses. The non-GAAP gross profit increase was primarily driven by product cost reductions, higher shipping volumes, increased factory capacity utilization in our ceramic capacitor and RF filter businesses, higher average pricing, and lower precious metal costs, partially offset by unfavorable product mix, lower than expected yields in our CD business as we ramp up our specialty film product line, and unfavorable inventory reserve adjustments.

Table of Contents

MedTech & Specialty Audio


	Nine Months Ended September 30,
(in millions)	2025		Percent of Revenues	2024		Percent of Revenues
Revenues	$	191.8		$	183.8



Earnings before interest and income taxes	$	65.3	34.0%	$	71.9	39.1%
Stock-based compensation expense	4.4			3.1

Impairment charges	3.6			—
Restructuring charges	0.3			—


Adjusted earnings before interest and income taxes	$	73.6	38.4%	$	75.0	40.8%

Revenues

MSA revenues were $191.8 million for the nine months ended September 30, 2025, compared with $183.8 million for the nine months ended September 30, 2024, an increase of $8.0 million or 4.4%. Revenues increased primarily due to higher shipping volumes of metal cans within the specialty audio market that we manufacture and sell to Syntiant as part of our supply agreement associated with the sale of CMM and additional higher shipping volumes into the specialty audio market, partially offset by lower average pricing on mature products and lower shipping volumes into the hearing health market.

Earnings and Adjusted Earnings Before Interest and Income Taxes

MSA EBIT was $65.3 million for the nine months ended September 30, 2025, compared with $71.9 million for the nine months ended September 30, 2024, a decrease of $6.6 million or 9.2%. EBIT margin for the nine months ended September 30, 2025 was 34.0%, compared with 39.1% for the nine months ended September 30, 2024. The decreases were primarily due to lower gross profit and higher operating expenses. The gross profit decrease was primarily due to higher factory costs, lower average pricing on mature products, impairment charges recorded in the second quarter of 2025, unfavorable product mix, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes and product cost reductions. The increase in operating expenses was primarily driven by higher stock-based compensation and legal costs.

MSA Adjusted EBIT was $73.6 million for the nine months ended September 30, 2025, compared with $75.0 million for the nine months ended September 30, 2024, a decrease of $1.4 million. Adjusted EBIT margin for the nine months ended September 30, 2025 was 38.4%, compared to 40.8% for the nine months ended September 30, 2024. The decreases were primarily due to higher non-GAAP operating expenses and lower non-GAAP gross profit. The increase in non-GAAP operating expenses was primarily driven by higher legal costs. The decrease in non-GAAP gross profit was primarily due to higher factory costs, lower average pricing on mature products, unfavorable product mix, and the impact of higher shipping volumes of our lower margin metal can products to Syntiant, partially offset by higher shipping volumes and product cost reductions.

Table of Contents

Liquidity and Capital Resources

Historically, we have generated and expect to continue to generate positive cash flow from operations. Our ability to fund our operations and capital needs will depend on our ongoing ability to generate cash from operations and access to capital markets. We believe that our future cash flow from operations and access to capital markets will provide adequate resources to fund our working capital needs, capital expenditures, strategic investments, and share repurchases. We have secured a revolving line of credit in the United States from a syndicate of commercial banks to provide additional liquidity. Furthermore, if we were to require additional cash above and beyond our cash on the balance sheet, the free cash flow generated by the business, and availability under our revolving credit facility, we would most likely seek to raise long-term financing through the U.S. debt or bank markets.

Due to the global nature of our operations, a portion of our cash is generated and typically held outside the United States. Our cash and cash equivalents totaled $92.5 million and $130.1 million at September 30, 2025 and December 31, 2024, respectively. Of these amounts, cash held by our non-U.S. operations totaled $21.2 million and $92.4 million as of September 30, 2025 and December 31, 2024, respectively. To the extent we repatriate these funds to the U.S., we may be required to pay U.S. state income taxes and applicable foreign withholding taxes on those amounts during the period when such repatriation occurs. Management will continue to reassess our need to repatriate the earnings of our foreign subsidiaries.

On December 27, 2024, we completed the sale of the CMM segment to Syntiant for approximately $141.9 million in total consideration, consisting of $63.6 million in cash ($58.0 million net of cash sold), Syntiant Series D-2 preferred stock with a fair value of $77.2 million, and $1.1 million for estimated purchase price adjustments. The purchase price adjustment amount is still being negotiated and is subject to change. For additional information, refer to Note 3. Discontinued Operations to our Consolidated Financial Statements. We will also share in certain separation costs pursuant to a credit for up to $13.5 million, which the buyer may apply to specified separation costs post-closing. As the balance of the separation credit is now below the $6.5 million contractual threshold, costs will be shared equally by the Company and Syntiant. For additional information, refer to Note 1. Basis of Presentation.

On February 24, 2020, we announced that our Board of Directors had authorized a share repurchase program of up to $100.0 million of our common stock. On April 28, 2022, we announced that our Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value, for a total of $400.0 million of aggregate value. At September 30, 2025, we have $139.0 million remaining that may yet be repurchased under our share repurchase program. The timing and amount of any shares repurchased will be determined by us based on our evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. We are not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock. During the nine months ended September 30, 2025 and 2024, the Company repurchased 3,120,574 and 1,686,253 shares of common stock, respectively, for a total of $55.0 million and $29.5 million, respectively.

Cash flows from operating, investing, and financing activities as reflected in our Consolidated Statements of Cash Flows and are presented on a consolidated basis, including discontinued operations. Cash flows are summarized in the following table:


	Nine Months Ended September 30,
(in millions)	2025		2024
Net cash flows provided by (used in):
Operating activities	$	66.8	$	95.0
Investing activities	(16.3)		(3.1)
Financing activities	(88.6)		(87.2)
Effect of exchange rate changes on cash and cash equivalents	0.5		0.6
Net (decrease) increase in cash and cash equivalents	$	(37.6)	$	5.3

Table of Contents

Operating Activities

Cash provided by operating activities adjusts net earnings for certain non-cash items, including impairment charges, depreciation expense, amortization of intangible assets, stock-based compensation, changes in deferred income taxes, and the effects of changes in operating assets and liabilities. The decrease in cash provided by operating activities in 2025 is primarily due to $31.2 million of payments in 2025 to settle supplier obligations and separation costs related to CMM and the absence of $22.1 million of cash generated by CMM in 2024. This decrease was partially offset by customer prepayments of $19.8 million, higher earnings from continuing operations, and lower interest payments in 2025.

Investing Activities

The cash used in investing activities during 2025 was driven by capital expenditures, which is primarily driven by capacity expansion related to our specialty film product line and cost savings. The cash used in investing activities during 2024 was primarily driven by capital expenditures, partially offset by proceeds from the sale of intellectual property.

In 2025, we expect capital expenditures to be in the range of 4% to 6% of revenues.

Financing Activities

Cash used in financing activities during 2025 was primarily related to $55.0 million of repurchases of common stock, $30.0 million of payments on the revolving credit facility, and $7.1 million of tax payments related to net share settlement of equity awards, partially offset by proceeds of $3.9 million from the exercise of options. Cash used in financing activities during 2024 was primarily related to $29.5 million of repurchases of common stock, $52.0 million net payments on the revolving credit facility, and $6.4 million for payment of taxes related to net share settlement of equity awards, partially offset by proceeds of $2.1 million from the exercise of options.

Adjusted Free Cash Flow

In addition to measuring cash flow generation based on the operating, investing, and financing classifications included in the Consolidated Statement of Cash Flows (including discontinued operations), Knowles also measures adjusted free cash flow and adjusted free cash flow as a percentage of revenues. Adjusted free cash flow is defined as non-GAAP net cash attributable to continuing operations less non-GAAP capital expenditures attributable to continuing operations. Non-GAAP net cash attributable to continuing operations is defined as net cash provided by operating activities less amounts generated or utilized by discontinued operations. Non-GAAP capital expenditures attributable to continuing operations is defined as capital expenditures less amounts attributable to discontinued operations. Knowles believes these measures are helpful in measuring its cash generated from its continuing operations that is available to repay debt, fund acquisitions, and repurchase Knowles common stock. Adjusted free cash flow and adjusted free cash flow as a percentage of revenues are not presented in accordance with GAAP and may not be comparable to similarly titled measures used by other companies in our industry. As such, adjusted free cash flow and adjusted free cash flow as a percentage of revenues should not be considered in isolation from, or as an alternative to, any other liquidity measures determined in accordance with GAAP.

Table of Contents

The following table reconciles our adjusted free cash flow to cash flow provided by operating activities:


	Nine Months Ended September 30,
(in millions)	2025			2024
Net cash provided by operating activities	$	66.8		$	95.0
Amounts utilized in (provided by) in discontinued operations	31.2			(22.1)
Non-GAAP net cash attributable to continuing operations	98.0			72.9

Capital expenditures	(16.8)			(10.3)
Amounts attributable to discontinued operations	—			0.9
Non-GAAP capital expenditures attributable to continuing operations	(16.8)			(9.4)

Non-GAAP net cash attributable to continuing operations	98.0			72.9
Non-GAAP capital expenditures attributable to continuing operations	(16.8)			(9.4)
Adjusted free cash flow	$	81.2		$	63.5

Adjusted free cash flow as a % of revenues	18.8		%	15.5		%

In 2025 we generated adjusted free cash flow of $81.2 million compared to adjusted free cash flow of $63.5 million in 2024. The increase in adjusted free cash flow in 2025 was primarily due to customer prepayments of $19.8 million, higher earnings from continuing operations, and lower interest payments, partially offset by higher capital expenditures and an increase in working capital.

Contingent Obligations

We are involved in various legal proceedings, claims, and investigations arising in the ordinary course of business. Legal contingencies are discussed in Note 14. Commitments and Contingent Liabilities to our Consolidated Financial Statements.

Critical Accounting Estimates

This discussion and analysis of results of operations and financial condition is based on our Consolidated Financial Statements, which have been prepared in conformity with U.S. GAAP. The preparation of these financial statements requires the use of estimates and assumptions related to the reporting of assets, liabilities, revenues, expenses, and related disclosures. In preparing these financial statements, we have made our best estimates and judgments of certain amounts included in the financial statements. Estimates are revised periodically. Actual results could differ from these estimates.

The information concerning our critical accounting estimates can be found under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 13, 2025. There are no material changes in our previously reported critical accounting estimates.

Recent Accounting Standards

The issuance of recent accounting standards, as included in Note 2. Recent Accounting Standards to our Consolidated Financial Statements, is not expected to have a significant impact on our revenue, earnings, or liquidity.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

During the nine months ended September 30, 2025, there were no material changes to the information on market risk exposure disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024. For a discussion of our exposure to market risk as of December 31, 2024, refer to Item 7A, Quantitative and Qualitative Disclosures about Market Risk, contained in our Annual Report on Form 10-K for the year ended December 31, 2024.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management has evaluated, under the supervision and with the participation of our chief executive officer ("CEO") and chief financial officer ("CFO"), the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on that evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) accumulated and communicated to our management, including our CEO and CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the third quarter of 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including the CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, will be detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by intentionally falsified documentation, by collusion of two or more individuals within Knowles or third parties, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

For a discussion of contingencies related to legal proceedings, see Note 14. Commitments and Contingent Liabilities to our Consolidated Financial Statements, which is incorporated herein by reference.

Except as otherwise noted above, there have been no material developments in legal proceedings.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

On February 24, 2020, the Company announced that its Board of Directors had authorized a share repurchase program of up to $100.0 million of the Company's common stock. On April 28, 2022, the Company announced that its Board of Directors had increased the authorization by up to $150.0 million in additional aggregate value. On February 13, 2025, the Company announced another authorization increase of up to $150.0 million in additional aggregate value. The timing and amount of any shares repurchased will be determined by the Company based on its evaluation of market conditions and other factors, and will be made in accordance with applicable securities laws in either the open market or in privately negotiated transactions. The Company is not obligated to purchase any shares under the program, and the program may be suspended or discontinued at any time. Any shares repurchased will be held as treasury stock.

Below is a summary of share repurchases for the three months ended September 30, 2025:


(in millions, except share and per share amounts)
Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Program	Approximate Dollar Value of Shares That May Yet Be Purchased Under The Program
July 2025	77,168	$	20.73	77,168	$	157.4
August 2025	411,653	$	20.53	411,653	$	149.0
September 2025	449,291	$	22.15	449,291	$	139.0
Total Activity	938,112	$	21.32	938,112

Item 5. Other Information

Director and Officer Trading Plans and Arrangements

Name (Title)

Action

Date

Trading Arrangement

Total Shares to be Sold

Expiration Date

Rule 10b5-1*

Non-Rule 10b5-1**

Jeffrey Niew

President & Chief Executive Officer

Adopt

8/13/2025

175,000

7/15/2026

John Anderson

Senior Vice President & Chief Financial Officer

Adopt

8/22/2025

41,400

8/21/2026

* Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)

** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)

Table of Contents

Item 6. Exhibits


31.1			Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2			Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1			Joint Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101			The following financial information from Knowles Corporation's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 formatted in Inline XBRL: (i) Consolidated Statements of Earnings (Unaudited) for the three and nine months ended September 30, 2025 and 2024, (ii) Consolidated Statements of Comprehensive Earnings (Unaudited) for the three and nine months ended September 30, 2025 and 2024, (iii) Consolidated Balance Sheets (Unaudited) as of September 30, 2025 and December 31, 2024, (iv) Consolidated Statements of Stockholders’ Equity (Unaudited) for the three and nine months ended September 30, 2025 and 2024, (v) Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2025 and 2024, and (vi) the Notes to the Consolidated Financial Statements (Unaudited) tagged as blocks of text and including detailed tags.

104			The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL and contained in Exhibit 101.

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		KNOWLES CORPORATION

Date:	October 28, 2025	/s/ John S. Anderson
		John S. Anderson
		Senior Vice President & Chief Financial Officer
		(Principal Financial Officer)

Knowles Corp 10-Q